risperidone and Affective Psychosis, Bipolar studies

Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.

Research Excerpts

Excerpt	Relevance	Reference
"The association between 5 ANKK1, 54 DRD2, and 11 HTR2C SNPs and weight change during 8 weeks of olanzapine treatment was assessed in 4 pooled studies of 205 white patients with diagnoses other than schizophrenia who were generally likely to have had limited previous antipsychotic exposure."	9.16	Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. ( Bishop, JR; Conley, RR; Ellingrod, VL; Fijal, BA; Houston, JP; Kohler, J; Ostbye, KM; Poole Hoffmann, V; Zhao, F, 2012)
"The objective of this exploratory analysis was to characterize efficacy and onset of action of a 3-month treatment period with risperidone long-acting injection (RLAI), adjunctive to an individual's treatment regimen, in subjects with symptomatic bipolar disorder who relapsed frequently and had significant symptoms of mania and/or depression."	9.15	Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms. ( Adler, CM; Alphs, L; Haskins, JT; Macfadden, W; Turkoz, I; Turner, N, 2011)
"On the last-observation-carried forward analysis of repeated measures analysis of variance (ANOVA), risperidone was not more effective than placebo for the CGI-21 Anxiety score or the other anxiety outcome measures."	9.14	Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. ( Gonzalez, R; Harnett-Sheehan, K; Janavs, J; Keck, PE; McElroy, SL; Rogers, J; Sheehan, DV; Shivakumar, G; Suppes, T, 2009)
"The use of ketamine for depression has increased rapidly in the past decades."	9.12	Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. ( Bakker, IM; Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Touw, DJ; Veraart, JKE; Visser, BAE, 2021)
"We searched MEDLINE, Central, EMBASE and PsycINFO until December 2020 for randomised placebo-controlled trials of Risperidone, Paliperidone or Paliperidone palmitate in patients with schizophrenia or bipolar disorder."	9.12	Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports. ( Heneghan, C; Hodkinson, A; Kontopantelis, E; Mahtani, KR; Panagioti, M, 2021)
"The aim of this study was to assess the safety and efficacy of risperidone augmentation of lithium in preschool-onset bipolar disorder (BD) among youth who insufficiently respond to lithium monotherapy."	9.12	A one-year open-label trial of risperidone augmentation in lithium nonresponder youth with preschool-onset bipolar disorder. ( Carbray, JA; Henry, DB; Janicak, PG; Naylor, MW; Pavuluri, MN; Sampson, GA, 2006)
"The effect of lamotrigine on the steady-state plasma concentrations of the atypical antipsychotics clozapine, olanzapine, and risperidone was investigated in patients with schizophrenia or bipolar disorder stabilized on chronic treatment with clozapine (200-500 mg/day; n = 11), risperidone (3-6 mg/day; n = 10) or olanzapine (10-20 mg/day; n = 14))."	9.12	Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. ( D'Amico, G; D'Arrigo, C; Micò, U; Migliardi, G; Muscatello, MR; Perucca, E; Santoro, V; Spina, E, 2006)
" The combination of risperidone and divalproex sodium is used to treat the manic phase of bipolar disorder."	9.11	Risperidone does not affect steady-state pharmacokinetics of divalproex sodium in patients with bipolar disorder. ( Alexander, J; Lacroix, D; Ravindran, A; Silverstone, P; van Schaick, E; Vermeulen, A, 2004)
"These pilot data, from the first prospective comparison study of risperidone and olanzapine in bipolar disorder, suggest that adjunctive administration of either agent may reduce depressive symptom severity."	9.11	The antidepressant effects of risperidone and olanzapine in bipolar disorder. ( Kennedy, SH; Konarski, JZ; Mancini, DA; McCann, S; McIntyre, RS; Srinivasan, J, 2004)
"The aim of this study was to evaluate the potential of risperidone as a treatment of pediatric bipolar disorder."	9.11	An open-label trial of risperidone in children and adolescents with bipolar disorder. ( Aleardi, M; Biederman, J; Faraone, SV; Mick, E; Spencer, T; Wozniak, J, 2005)
"To evaluate short-term safety and efficacy of atypical antipsychotics in a single-site, prospective, open-label, 8-week study of risperidone and olanzapine monotherapy in preschoolers with bipolar disorder (BPD)."	9.11	Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. ( Aleardi, M; Biederman, J; Dougherty, M; Hammerness, P; Harpold, T; Mick, E; Wozniak, J, 2005)
"Risperidone, an atypical neuroleptic, has been proposed for augmentation strategies in resistant obsessive-compulsive disorder (OCD)."	9.09	Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. ( Cassano, GB; Dell'Osso, L; Gemignani, A; Marazziti, D; Milanfranchi, A; Pfanner, C; Presta, S, 2000)
"A retrospective study of the Massachusetts General Hospital Bipolar Clinic database was carried out to identify 50 consecutive treatment trials in patients with DSM-IV bipolar disorder type I who had received adjunctive treatment with risperidone, olanzapine, or clozapine, along with standard mood stabilizers."	9.09	A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. ( Ghaemi, SN; Guille, C; Sachs, GS, 2000)
"Outpatients who fulfilled DSM-IV criteria for bipolar I, bipolar II, or major depressive disorder and suffered from psychosis or agitation associated with their illness (N = 20) and those who had treatment-refractory DSM-IV OCD (N = 5) were started on open trials of risperidone at daily doses of 1 to 1."	9.08	Risperidone in the treatment of affective illness and obsessive-compulsive disorder. ( Jacobsen, FM, 1995)
"Risperidone was used to treat 11 elderly hospitalized patients between 61 and 79 years of age who manifested signs of psychoses related to schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia."	9.08	Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. ( Abaza, A; Araujo, L; Brenner, R; Madhusoodanan, S, 1995)
"To assess the randomised evidence for the efficacy and tolerability of risperidone compared with placebo or other active pharmacological treatments as long-term treatment for prevention or attenuation of further episodes of mood disorder in patients with bipolar disorder."	8.83	Risperidone in long-term treatment for bipolar disorder. ( Geddes, JR; Rendell, JM, 2006)
"Antipsychotic drugs plus aspirin (acetylsalicylic acid), which targets prostaglandin-endoperoxide synthase 1 (PTGS1: COX1), improved therapeutic outcomes when treating schizophrenia."	7.88	Studies on Prostaglandin-Endoperoxide Synthase 1: Lower Levels in Schizophrenia and After Treatment with Antipsychotic Drugs in Conjunction with Aspirin. ( Dean, B; Gibbons, A; Gogos, A; Scarr, E; Thomas, E; Udawela, M, 2018)
"The aim of this study was to compare the treatment effectiveness between long-acting injectable risperidone and long-acting injectable first-generation antipsychotics among patients with bipolar disorder."	7.83	Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder. ( Chang, CJ; Hsieh, MH; Tang, CH; Wu, CS, 2016)
"Baseline body mass index (BMI), baseline BMI status (normal, overweight, obese) and early (1 month) BMI increases were tested as predictors of 6- and 12-month increases in glucose and lipid measures in 82 olanzapine (OLZ)- and 78 risperidone (RIS)-treated patients with schizophrenia, schizoaffective disorder, or bipolar disorder who participated in a 12-month randomized, prospective metabolic effects study."	7.77	Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder. ( Bobo, WV; Bonaccorso, S; Jayathilake, K; Meltzer, HY, 2011)
"Risperidone, as all atypical antipsychotics, can cause hyperprolactinemia which can in turn lead to galactorrhea."	7.76	Galactorrhea - side effect of risperidone in combination with depakine chrono in a patient with bipolar disorder. ( Grahovac, T; Pavlović, E; Peitl, MV; Peitl, V, 2010)
"To examine the safety and efficacy of liquid risperidone to reduce duration of rages in children with severe mood dysregulation (SMD) or possible bipolar disorder (BP)."	7.76	Liquid risperidone in the treatment of rages in psychiatrically hospitalized children with possible bipolar disorder. ( Basile, J; Carlson, GA; Gutkovich, Z; Margulies, D; Potegal, M, 2010)
"To compare clinical responses of patients with pediatric bipolar disorder being treated with risperidone versus divalproex."	7.74	Comparative clinical responses to risperidone and divalproex in patients with pediatric bipolar disorder. ( Gonzalez-Heydrich, JM; Korndörfer, SR; MacMillan, CM; Mrakotsky, C; Tilley, CA; Withney, JE, 2008)
"The purpose of this study was to investigate the anterior cingulate cortex (ACC) glutamate/glutamine (Glx) to creatine ratio (Glx/Cr) in two groups of children with Bipolar Disorder (BPD): those exhibiting manic symptoms requiring treatment and those being stably treated with the atypical antipsychotic risperidone."	7.74	Mania, glutamate/glutamine and risperidone in pediatric bipolar disorder: a proton magnetic resonance spectroscopy study of the anterior cingulate cortex. ( Aleardi, M; Biederman, J; Dougherty, M; Hammerness, P; Harpold, T; Lyoo, IK; Mick, E; Moore, CM; Randall, E; Renshaw, PF; Wardrop, M; Wozniak, J, 2007)
"This case report describes two children who developed hyperammonemia together with frank manic behavior during treatment with a combination of valproic acid and risperidone."	7.74	Case report: valproic Acid and risperidone treatment leading to development of hyperammonemia and mania. ( Caplan, R; Carlson, T; Reynolds, CA, 2007)
"Total charges for mental health services other than the study drug were not different for risperidone, olanzapine, and quetiapine in patients treated for bipolar disorder."	7.73	Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine. ( Gianfrancesco, F; Pesa, J; Wang, RH, 2005)
" The first reported case of quetiapine and citalopram-associated serotonin syndrome is discussed with reference to a Medline, Embase, and PsycINFO literature search."	7.73	Quetiapine and citalopram: aetiological significances in serotonin syndrome. ( Marlowe, K; Schirgel, D, 2006)
"To evaluate the effectiveness and safety of risperidone in children and adolescents with bipolar disorder characterized by aggression and mania, despite treatment with mood stabilizers."	7.73	Treatment of aggression with risperidone in children and adolescents with bipolar disorder: a case series. ( Chang, K; Saxena, K; Steiner, H, 2006)
" We report a case of exaggerated hypotension during a spinal anesthetic for cesarean delivery that may have been a result of the alpha-adrenergic antagonism of risperidone."	7.72	Risperidone and exaggerated hypotension during a spinal anesthetic. ( Hepner, DL; Williams, JH, 2004)
"We report a 5-case series in which risperidone use in usual or lower-than-usual doses was unexpectedly associated with amenorrhea."	7.70	Risperidone and associated amenorrhea: a report of 5 cases. ( Kim, L; Kim, YK; Lee, MS, 1999)
"This is a retrospective chart review of outpatients with the diagnosis of bipolar disorder (DSM-IV) treated with risperidone at a university center."	7.70	Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. ( Biederman, J; Frazier, JA; Kim, GS; Meyer, MC; Shapiro, S; Spencer, TJ; Wilens, TE; Wozniak, J, 1999)
"Patients displaying a moderate-to-marked response to risperidone were more likely to be younger; receive diagnoses of bipolar disorder or schizoaffective disorder, depressive type; and have a shorter duration of illness and shorter length of stay prior to risperidone treatment."	7.69	Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. ( Balistreri, TM; DePriest, M; Holtman, HM; Keck, PE; Kizer, DL; McElroy, SL; Strakowski, SM; Wilson, DR, 1995)
"To describe a case of neuroleptic malignant syndrome associated with risperidone."	7.69	Neuroleptic malignant syndrome and risperidone: a case report. ( Bonwick, RJ; Hopwood, MJ; Morris, PL, 1996)
"To test the hypothesis that, although typical neuroleptics are commonly used in the treatment of bipolar disorder, newer atypical antipsychotic agents, like risperidone, may be more effective and better-tolerated."	7.69	Acute treatment of bipolar disorder with adjunctive risperidone in outpatients. ( Baldassano, CF; Ghaemi, SN; Sachs, GS; Truman, CJ, 1997)
" Safety measures included body mass index, serum prolactin, extrapyramidal adverse effects, and electrocardiogram."	6.80	Efficacy and Safety of Risperidone and Quetiapine in Adolescents With Bipolar II Disorder Comorbid With Conduct Disorder. ( Masi, G; Milone, A; Pisano, S; Stawinoga, A; Veltri, S, 2015)
"Co-morbid diagnoses, such as disruptive behavior disorders (DBDs) and high levels of aggression, are extremely common among youth with pediatric bipolar disorder (PBD) and may interfere with treatment response; however, they have rarely been examined as predictors of response to pharmacotherapy."	6.76	Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder. ( Celio, CI; Henry, D; Pavuluri, MN; Weinstein, SM; West, AE, 2011)
" However, there are important limitations to the long-term use of depot typical neuroleptics in patients with bipolar disorder, including risk of extrapyramidal side effects and tardive dyskinesia, which may exceed that of patients with schizophrenia, and the potential for treatment-emergent exacerbation of depressive symptoms."	6.46	Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder. ( Bobo, WV; Shelton, RC, 2010)
"Risperidone has also been reported to be useful in the longer-term treatment of bipolar disorder."	6.43	Risperidone for bipolar disorders. ( Aulakh, L; Fuller, MA; Keaton, DB; Madhusoodanan, S; Sajatovic, M, 2005)
"This is a double-blind, placebo-controlled, parallel-grouped clinical trial, which was designed to investigate the potential effects of melatonin add-on treatment with lithium and risperidone on acute manic episodes in patients with bipolar disorder (BD)."	5.34	Efficacy of melatonin as an adjunct in the treatment of acute mania: a double-blind and placebo-controlled trial. ( Akhondzadeh, S; Bahmani, S; Bayanati, S; Mahdavinasa, M; Moghaddam, HS; Rezaei, F, 2020)
"Risperidone was switched to another antipsychotic."	5.34	Risperidone-induced polydipsia and polyphagia associated with galactorrhea, abdominal pain, and rapid weight gain in an adolescent Hispanic female. ( Afzal, KI; Briones, DF; DeVargas, C, 2007)
"We accepted him as type 1 diabetes mellitus (DM type 1)."	5.33	Risperidone-associated transient diabetic ketoacidosis and diabetes mellitus type 1 in a patient treated with valproate and lithium. ( Alpaslan, T; Bulent, C; Cengiz, T; Mithat, B, 2005)
"Risperidone, an atypical antipsychotic medication, is recommended as a first line treatment for acute mania in patients with bipolar disorder I (BD I)."	5.30	Risperidone adjunctive therapy duration in the maintenance treatment of bipolar I disorder: A post hoc analysis. ( Bertolin, S; Lam, RW; Qian, H; Valdes, M; Wong, H; Yatham, LN, 2019)
"Valnoctamide did not differ significantly from placebo on any of the study endpoints (YMRS, Positive and Negative Syndrome Scale, and the Clinical Global Impression Scale for Bipolar Disorder [CGI-BP] scales; all P>."	5.24	A randomized, double-blind, placebo- and risperidone-controlled study on valnoctamide for acute mania. ( Bialer, M; Cirjaliu, D; Davis, JM; Levi, L; Levine, SZ; Matei, V; Sava, C; Shekh-Ahmad, T; Sinita, E; Tiugan, A; Weiser, M; Zamora, D, 2017)
", Text Revision (DSM-IV-TR) diagnosis of bipolar disorder, manic, hypomanic, or mixed episode, were recruited over a 6 year period from two academic outpatient programs for a double-blinded, placebo-controlled trial in which subjects were randomized in a 2:2:1 ratio to risperidone solution, valproic acid, or placebo."	5.20	Placebo-controlled trial of valproic Acid versus risperidone in children 3-7 years of age with bipolar I disorder. ( Altaye, M; Delgado, S; Kowatch, RA; Lagory, D; Monroe, E; Scheffer, RE, 2015)
"The current study examined the impact of risperidone and divalproex on affective and working memory circuitry in patients with pediatric bipolar disorder (PBD)."	5.16	Risperidone and divalproex differentially engage the fronto-striato-temporal circuitry in pediatric mania: a pharmacological functional magnetic resonance imaging study. ( Fitzgerald, JM; Passarotti, AM; Pavuluri, MN; Sweeney, JA; Wegbreit, E, 2012)
"TEAM was a multi-site, 8-week, randomized clinical trial of risperidone, lithium, or divalproex in 279 medication-naïve patients, aged 6 through 15 years, with a DSM-IV diagnosis of bipolar disorder currently in manic or mixed phase."	5.16	Treatment moderators and predictors of outcome in the Treatment of Early Age Mania (TEAM) study. ( Axelson, DA; Birmaher, B; Emslie, G; Joshi, P; Luby, J; Riddle, MA; Robb, A; Ryan, ND; Tillman, R; Vitiello, B; Wagner, KD; Walkup, JT; Yenokyan, G, 2012)
"The association between 5 ANKK1, 54 DRD2, and 11 HTR2C SNPs and weight change during 8 weeks of olanzapine treatment was assessed in 4 pooled studies of 205 white patients with diagnoses other than schizophrenia who were generally likely to have had limited previous antipsychotic exposure."	5.16	Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. ( Bishop, JR; Conley, RR; Ellingrod, VL; Fijal, BA; Houston, JP; Kohler, J; Ostbye, KM; Poole Hoffmann, V; Zhao, F, 2012)
"This study compares the metabolic effects of olanzapine and risperidone in a prospective, randomized, open-label trial in 160 patients with DSM-IV-TR schizophrenia, schizoaffective disorder, or bipolar disorder after 1, 3, 6, and 12 months' treatment."	5.15	A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. ( Bobo, WV; Bonaccorso, S; Chen, Y; Jayathilake, K; Meltzer, HY, 2011)
"The objective of this exploratory analysis was to characterize efficacy and onset of action of a 3-month treatment period with risperidone long-acting injection (RLAI), adjunctive to an individual's treatment regimen, in subjects with symptomatic bipolar disorder who relapsed frequently and had significant symptoms of mania and/or depression."	5.15	Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms. ( Adler, CM; Alphs, L; Haskins, JT; Macfadden, W; Turkoz, I; Turner, N, 2011)
"On the last-observation-carried forward analysis of repeated measures analysis of variance (ANOVA), risperidone was not more effective than placebo for the CGI-21 Anxiety score or the other anxiety outcome measures."	5.14	Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. ( Gonzalez, R; Harnett-Sheehan, K; Janavs, J; Keck, PE; McElroy, SL; Rogers, J; Sheehan, DV; Shivakumar, G; Suppes, T, 2009)
"The combination of risperidone with mood stabilizers was an effective and safe treatment for manic symptoms and coexisting depressive symptoms of bipolar disorder."	5.14	Risperidone in the treatment of mixed state bipolar patients: results from a 24-week, multicenter, open-label study in Korea. ( Ahn, YM; Bahk, WM; Cho, HS; Chung, SK; Hwang, TY; Jon, DI; Kim, JG; Lee, HS; Lee, KU; Lee, SY; Min, KJ; Pae, CU; Woo, YS; Yoon, BH, 2010)
"Data from the EMBLEM Study, a 2-year, prospective, observational study of health outcomes associated with acute treatment of patients experiencing a manic/mixed episode of bipolar disorder, was used to compare the effectiveness of olanzapine monotherapy versus risperidone monotherapy, and to investigate whether the treatment effects were similar to those reported in a 3-week, randomized controlled trial assessing the same treatments."	5.14	Comparison of olanzapine and risperidone in the EMBLEM Study: translation of randomized controlled trial findings into clinical practice. ( Aguado, J; Gonzalez-Pinto, A; Haro, JM; Novick, D; Perrin, E; Reed, C; Tohen, M, 2010)
"Valnoctamide could be an important valproate substitute for women of childbearing age with bipolar disorder who may become pregnant."	5.14	Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial. ( Agam, G; Applebaum, J; Belmaker, RH; Bersudsky, Y; Gaiduk, Y; Mishory, A; Podberezsky, A; Sharony, L, 2010)
"The use of ketamine for depression has increased rapidly in the past decades."	5.12	Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. ( Bakker, IM; Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Touw, DJ; Veraart, JKE; Visser, BAE, 2021)
"We searched MEDLINE, Central, EMBASE and PsycINFO until December 2020 for randomised placebo-controlled trials of Risperidone, Paliperidone or Paliperidone palmitate in patients with schizophrenia or bipolar disorder."	5.12	Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports. ( Heneghan, C; Hodkinson, A; Kontopantelis, E; Mahtani, KR; Panagioti, M, 2021)
"The aim of this study was to assess the safety and efficacy of risperidone augmentation of lithium in preschool-onset bipolar disorder (BD) among youth who insufficiently respond to lithium monotherapy."	5.12	A one-year open-label trial of risperidone augmentation in lithium nonresponder youth with preschool-onset bipolar disorder. ( Carbray, JA; Henry, DB; Janicak, PG; Naylor, MW; Pavuluri, MN; Sampson, GA, 2006)
"The effect of lamotrigine on the steady-state plasma concentrations of the atypical antipsychotics clozapine, olanzapine, and risperidone was investigated in patients with schizophrenia or bipolar disorder stabilized on chronic treatment with clozapine (200-500 mg/day; n = 11), risperidone (3-6 mg/day; n = 10) or olanzapine (10-20 mg/day; n = 14))."	5.12	Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. ( D'Amico, G; D'Arrigo, C; Micò, U; Migliardi, G; Muscatello, MR; Perucca, E; Santoro, V; Spina, E, 2006)
" The primary objective of this double-blind study was to compare the effects of treatment initiation with risperidone and quetiapine on cognitive function in subjects with stable bipolar disorder."	5.12	Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study. ( Engelhart, LM; Gharabawi, GM; Harvey, PD; Hassman, H; Mahmoud, RA; Mao, L, 2007)
" The combination of risperidone and divalproex sodium is used to treat the manic phase of bipolar disorder."	5.11	Risperidone does not affect steady-state pharmacokinetics of divalproex sodium in patients with bipolar disorder. ( Alexander, J; Lacroix, D; Ravindran, A; Silverstone, P; van Schaick, E; Vermeulen, A, 2004)
"These pilot data, from the first prospective comparison study of risperidone and olanzapine in bipolar disorder, suggest that adjunctive administration of either agent may reduce depressive symptom severity."	5.11	The antidepressant effects of risperidone and olanzapine in bipolar disorder. ( Kennedy, SH; Konarski, JZ; Mancini, DA; McCann, S; McIntyre, RS; Srinivasan, J, 2004)
"This prospective 6-month open trial examined the safety and efficacy of two combination therapies for manic or mixed episodes of pediatric bipolar disorder: (1) divalproex sodium plus risperidone (DVPX+Risp), or (2) lithium plus risperidone (Li+Risp)."	5.11	Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. ( Carbray, JA; Henry, DB; Janicak, PG; Naylor, MW; Pavuluri, MN; Sampson, G, 2004)
" The current study was intended to evaluate the effects of the novel antipsychotic risperidone, the selective serotonin reup-take inhibitor (SSRI) paroxetine, and the combination in patients with bipolar disorder."	5.11	Risperidone and paroxetine given singly and in combination for bipolar depression. ( Shelton, RC; Stahl, SM, 2004)
"The aim of this study was to evaluate the potential of risperidone as a treatment of pediatric bipolar disorder."	5.11	An open-label trial of risperidone in children and adolescents with bipolar disorder. ( Aleardi, M; Biederman, J; Faraone, SV; Mick, E; Spencer, T; Wozniak, J, 2005)
"To evaluate short-term safety and efficacy of atypical antipsychotics in a single-site, prospective, open-label, 8-week study of risperidone and olanzapine monotherapy in preschoolers with bipolar disorder (BPD)."	5.11	Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. ( Aleardi, M; Biederman, J; Dougherty, M; Hammerness, P; Harpold, T; Mick, E; Wozniak, J, 2005)
"A number of open studies and preliminary results of unpublished double-blind trials have suggested that the novel antipsychotic risperidone may be effective and well tolerated in the treatment of acute mania in bipolar disorder."	5.10	Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain. ( Benabarre, A; Fernández, A; Goikolea, JM; Herraiz, M; Parramon, G; Vieta, E, 2002)
"Subjects (N = 58) who met DSM-IV criteria for bipolar disorder and for a manic episode received both risperidone and topiramate for the treatment of their manic symptoms."	5.10	1-year follow-up of patients treated with risperidone and topiramate for a manic episode. ( Colom, F; Comes, M; Goikolea, JM; González-Pinto, A; Olivares, JM; Rodriguez, A; Sánchez-Moreno, J; Torrent, C; Vieta, E, 2003)
"The effects of haloperidol, risperidone, and thioridazine on the pharmacokinetics and side-effect profile of quetiapine were investigated in 36 patients with schizophrenia, schizoaffective disorder, or bipolar disorder in a single-center, two-period, multiple-dose, open-label, randomized trial."	5.10	The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. ( Alva, G; Arvanitis, LA; Bera, R; Potkin, SG; Thyrum, PT; Yeh, C, 2002)
"This 3-week randomized, double-blind, placebo-controlled study included 156 bipolar disorder patients with a current manic or mixed episode who received a mood stabilizer (lithium or divalproex) and placebo, risperidone, or haloperidol."	5.10	Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. ( Bowden, CL; Ghaemi, SN; Grossman, F; Okamoto, A; Sachs, GS, 2002)
"Risperidone, an atypical neuroleptic, has been proposed for augmentation strategies in resistant obsessive-compulsive disorder (OCD)."	5.09	Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. ( Cassano, GB; Dell'Osso, L; Gemignani, A; Marazziti, D; Milanfranchi, A; Pfanner, C; Presta, S, 2000)
"A retrospective study of the Massachusetts General Hospital Bipolar Clinic database was carried out to identify 50 consecutive treatment trials in patients with DSM-IV bipolar disorder type I who had received adjunctive treatment with risperidone, olanzapine, or clozapine, along with standard mood stabilizers."	5.09	A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. ( Ghaemi, SN; Guille, C; Sachs, GS, 2000)
"Outpatients who fulfilled DSM-IV criteria for bipolar I, bipolar II, or major depressive disorder and suffered from psychosis or agitation associated with their illness (N = 20) and those who had treatment-refractory DSM-IV OCD (N = 5) were started on open trials of risperidone at daily doses of 1 to 1."	5.08	Risperidone in the treatment of affective illness and obsessive-compulsive disorder. ( Jacobsen, FM, 1995)
"Risperidone was used to treat 11 elderly hospitalized patients between 61 and 79 years of age who manifested signs of psychoses related to schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia."	5.08	Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. ( Abaza, A; Araujo, L; Brenner, R; Madhusoodanan, S, 1995)
"Second-generation LAI antipsychotics, particularly risperidone and aripiprazole LAI, may be a safe and effective alternative to oral medications in the management of bipolar disorder."	5.01	Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review. ( Chakrabarty, T; Keramatian, K; Yatham, LN, 2019)
"Cariprazine was approved for treating schizophrenia and bipolar disorder, and currently is being evaluated for treating depression in clinical trials in the United States."	4.98	Use of cariprazine in psychiatric disorders: A systematic review. ( Chhatlani, A; Farheen, SA; Setty, MJ; Tampi, RR, 2018)
"Data available for the clinician assessing the interests of second-generation antipsychotics depot in long-term treatment of bipolar disorder are limited to risperidone."	4.90	What is the evidence for the use of second-generation antipsychotic long-acting injectables as maintenance treatment in bipolar disorder? ( Charpeaud, T; Llorca, PM; Nourry, A; Samalin, L, 2014)
" Several treatments [monoamine oxidase inhibitors (MAOIs), ziprasidone, aripiprazole and risperidone] have limited or no therapeutic activity in bipolar depression."	4.90	Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. ( Cornelius, V; Smith, L; Taylor, DM; Young, AH, 2014)
"Treatment of acute mania with second-generation antipsychotics has been claimed to involve a lower risk of switch to depression than haloperidol."	4.89	Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. ( Capapey, J; Colom, F; Goikolea, JM; Grande, I; Sanchez-Moreno, J; Torres, I; Undurraga, J; Valentí, M; Vieta, E, 2013)
"This paper comprises a review and commentary regarding the use of risperidone LAI in bipolar disorder."	4.86	Risperidone long-acting injection as monotherapy and adjunctive therapy in the maintenance treatment of bipolar I disorder. ( Casamassima, F; Fagiolini, A; Forgione, R; Goldstein, BI; Goracci, A; Mostacciuolo, W, 2010)
"To retrospectively examine published cases of neuroleptic malignant syndrome (NMS) in patients aged 18 and below who had been treated with atypical antipsychotics (clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole)."	4.84	Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. ( Croarkin, PE; Emslie, GJ; Mayes, TL, 2008)
"Randomised trials comparing haloperidol with placebo or other active treatment in the treatment of acute manic or mixed episodes in patients with bipolar disorder or schizoaffective disorder."	4.83	Haloperidol alone or in combination for acute mania. ( Cipriani, A; Geddes, JR; Rendell, JM, 2006)
"To assess the randomised evidence for the efficacy and tolerability of risperidone compared with placebo or other active pharmacological treatments as long-term treatment for prevention or attenuation of further episodes of mood disorder in patients with bipolar disorder."	4.83	Risperidone in long-term treatment for bipolar disorder. ( Geddes, JR; Rendell, JM, 2006)
"The role of lithium carbonate in the maintenance treatment of bipolar disorder is well established."	4.82	Alternatives to lithium and divalproex in the maintenance treatment of bipolar disorder. ( Freeman, MP; Gelenberg, AJ; Gnanadesikan, M, 2003)
"There is a now a substantial body of evidence that suggests the new antipsychotic agent, risperidone, may be safe and effective for treating psychotic, affective or behavioural symptoms associated with various disorders other than schizophrenia, schizophreniform disorder or schizo-affective disorder."	4.81	Does risperidone have a place in the treatment of nonschizophrenic patients? ( Schweitzer, I, 2001)
"Relevant data relating to the dosage of risperidone identified through an online (MEDLINE) search using the keywords risperidone, schizophrenia, schizoaffective disorder dementia, bipolar disorder, and dose were supplemented by a review of international and U."	4.81	Optimal dosing with risperidone: updated recommendations. ( Williams, R, 2001)
"The authors' goal was to analyze reported cases of neuroleptic malignant syndrome in patients given clozapine and risperidone."	4.80	Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. ( Buckley, P; Hasan, S, 1998)
"This study enrolled adults with schizophrenia or bipolar I disorder who initiated APT treatment at various time points: 1) within 8 weeks of initiating risperidone long-acting injectables (RLAIs) or other APTs except paliperidone palmitate (PP), 2) after more than 24 weeks of continuous RLAI treatment, or 3) at any time after initiating PP LAI treatment (schizophrenia only)."	3.88	The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia. ( Biondi, DM; Joshi, K; Mao, L; Millet, R, 2018)
"Antipsychotic drugs plus aspirin (acetylsalicylic acid), which targets prostaglandin-endoperoxide synthase 1 (PTGS1: COX1), improved therapeutic outcomes when treating schizophrenia."	3.88	Studies on Prostaglandin-Endoperoxide Synthase 1: Lower Levels in Schizophrenia and After Treatment with Antipsychotic Drugs in Conjunction with Aspirin. ( Dean, B; Gibbons, A; Gogos, A; Scarr, E; Thomas, E; Udawela, M, 2018)
"The aim of this study was to compare the treatment effectiveness between long-acting injectable risperidone and long-acting injectable first-generation antipsychotics among patients with bipolar disorder."	3.83	Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder. ( Chang, CJ; Hsieh, MH; Tang, CH; Wu, CS, 2016)
" Given the scarcity of adequate data on its prenatal toxicity, a comparative teratogenicity study of valnoctamide and two of the most commonly used drugs to treat bipolar disorder, risperidone and olanzapine, was carried out in a mouse model system."	3.81	Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice. ( Bialer, M; Finnell, RH; Lin, LY; Ogle, K; Wlodarczyk, BJ, 2015)
"Using Mixed Model Repeated Measures, we tested the relationship between SULT4A1-1 status (+carrier, -noncarrier) and clinical improvement (in Positive and Negative Syndrome Scale total score) among European ancestry patients treated with paliperidone extended release (n=937), paliperidone palmitate (n=990), risperidone (n=507) and olanzapine (n=381) in 12 schizophrenia, two schizoaffective disorder and three bipolar I disorder trials."	3.80	SULT4A1 haplotype: conflicting results on its role as a biomarker of antipsychotic response. ( Chung, H; Cohen, N; Favis, R; Fu, DJ; Gopal, S; Jadwin, A; Li, Q; Savitz, A; Wang, D, 2014)
"A 19-year-old man with schizophrenia and underlying cerebral disease developed rapid-onset mania after risperidone was replaced with amisulpride."	3.80	Amisulpride-associated mania in a young adult with schizophrenia and cerebral disease. ( Chen, CY; Chen, TY; Chuang, WC; Kuo, SC; Yeh, YW, 2014)
"Data were derived from the national Department of Veterans Affairs registries for older patients with bipolar disorder (≥65 years) with a new start of an atypical antipsychotic (risperidone, olanzapine, or quetiapine) or valproic acid and derivatives during fiscal years 2001-2008."	3.78	Mortality risk with the use of atypical antipsychotics in later-life bipolar disorder. ( Bhalerao, S; Chiang, C; Kales, HC; Kavanagh, J; Kim, HM; Seyfried, LS, 2012)
"Baseline body mass index (BMI), baseline BMI status (normal, overweight, obese) and early (1 month) BMI increases were tested as predictors of 6- and 12-month increases in glucose and lipid measures in 82 olanzapine (OLZ)- and 78 risperidone (RIS)-treated patients with schizophrenia, schizoaffective disorder, or bipolar disorder who participated in a 12-month randomized, prospective metabolic effects study."	3.77	Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder. ( Bobo, WV; Bonaccorso, S; Jayathilake, K; Meltzer, HY, 2011)
"To identify the factors associated with newly prescribed, first-line, second-generation antipsychotics (SgAs) associated with weight gain-olanzapine, risperidone, and quetiapine."	3.77	Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders. ( Arndt, S; Chrischilles, EA; Coryell, WH; Ellingrod, VL; Fiedorowicz, JG; Haynes, WG; Miller, del D; Prabhakar, M; Warren, L, 2011)
"Risperidone, as all atypical antipsychotics, can cause hyperprolactinemia which can in turn lead to galactorrhea."	3.76	Galactorrhea - side effect of risperidone in combination with depakine chrono in a patient with bipolar disorder. ( Grahovac, T; Pavlović, E; Peitl, MV; Peitl, V, 2010)
"This 12-month, prospective, observational study investigated factors associated with symptomatic remission (total YMRS score < or =12) and full clinical recovery (sustained reduction in CGI-BP-S overall score) in bipolar disorder during treatment with atypical antipsychotics (predominantly olanzapine, risperidone and quetiapine; alone or in combination with a psychotropic such as lithium or valproate) in actual clinical practice."	3.76	Twelve-month prospective, multinational, observational study of factors associated with recovery from mania in bipolar disorder in patients treated with atypical antipsychotics. ( Badr, MG; D'yachkova, Y; Dikeos, D; Fábián, Z; Harrison, G; Hudiţă, C; Okasha, T; Pesek, MB; Tapia-Paniagua, G; Treuer, T; Yang, F, 2010)
"To examine the safety and efficacy of liquid risperidone to reduce duration of rages in children with severe mood dysregulation (SMD) or possible bipolar disorder (BP)."	3.76	Liquid risperidone in the treatment of rages in psychiatrically hospitalized children with possible bipolar disorder. ( Basile, J; Carlson, GA; Gutkovich, Z; Margulies, D; Potegal, M, 2010)
"Asenapine is a novel psychopharmacologic agent under development for the treatment of schizophrenia and bipolar disorder."	3.75	Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. ( Shahid, M; Walker, GB; Wong, EH; Zorn, SH, 2009)
"To compare clinical responses of patients with pediatric bipolar disorder being treated with risperidone versus divalproex."	3.74	Comparative clinical responses to risperidone and divalproex in patients with pediatric bipolar disorder. ( Gonzalez-Heydrich, JM; Korndörfer, SR; MacMillan, CM; Mrakotsky, C; Tilley, CA; Withney, JE, 2008)
"The purpose of this study was to investigate the anterior cingulate cortex (ACC) glutamate/glutamine (Glx) to creatine ratio (Glx/Cr) in two groups of children with Bipolar Disorder (BPD): those exhibiting manic symptoms requiring treatment and those being stably treated with the atypical antipsychotic risperidone."	3.74	Mania, glutamate/glutamine and risperidone in pediatric bipolar disorder: a proton magnetic resonance spectroscopy study of the anterior cingulate cortex. ( Aleardi, M; Biederman, J; Dougherty, M; Hammerness, P; Harpold, T; Lyoo, IK; Mick, E; Moore, CM; Randall, E; Renshaw, PF; Wardrop, M; Wozniak, J, 2007)
"This case report describes two children who developed hyperammonemia together with frank manic behavior during treatment with a combination of valproic acid and risperidone."	3.74	Case report: valproic Acid and risperidone treatment leading to development of hyperammonemia and mania. ( Caplan, R; Carlson, T; Reynolds, CA, 2007)
"To evaluate dose effect in response on primary efficacy scales from 2 randomized, double-blind, flexible-dose trials of patients with bipolar mania who received olanzapine (N = 234, 5-20 mg/day), or patients with schizophrenia who received olanzapine (N = 172, 10-20 mg/day), we used marginal structural models, inverse probability of treatment weighting (MSM, IPTW) methodology."	3.74	Evaluating dose response from flexible dose clinical trials. ( Adams, DH; Baron, D; Faries, D; Houston, JP; Lipkovich, I; Mallinckrodt, C, 2008)
"A patient of bipolar disorder, who presented with manic symptoms with psychotic feature, started with a combination of lithium and risperidone."	3.74	Encephalopathy with combined lithium-risperidone administration. ( Boora, K; Hyatt, J; Xu, J, 2008)
"Clozapine had a significantly lower discontinuation rate in individuals with schizophrenia, compared to the other 4 SGAs."	3.74	Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study. ( Lawrie, SM; Shajahan, P; Taylor, M, 2008)
"Total charges for mental health services other than the study drug were not different for risperidone, olanzapine, and quetiapine in patients treated for bipolar disorder."	3.73	Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine. ( Gianfrancesco, F; Pesa, J; Wang, RH, 2005)
" The first reported case of quetiapine and citalopram-associated serotonin syndrome is discussed with reference to a Medline, Embase, and PsycINFO literature search."	3.73	Quetiapine and citalopram: aetiological significances in serotonin syndrome. ( Marlowe, K; Schirgel, D, 2006)
"To evaluate the effectiveness and safety of risperidone in children and adolescents with bipolar disorder characterized by aggression and mania, despite treatment with mood stabilizers."	3.73	Treatment of aggression with risperidone in children and adolescents with bipolar disorder: a case series. ( Chang, K; Saxena, K; Steiner, H, 2006)
" We report a case of exaggerated hypotension during a spinal anesthetic for cesarean delivery that may have been a result of the alpha-adrenergic antagonism of risperidone."	3.72	Risperidone and exaggerated hypotension during a spinal anesthetic. ( Hepner, DL; Williams, JH, 2004)
"Risperidone induced galactorrhea and hyperprolactinemia have been reported but its role in the growth of prolactinoma is not yet conclusive, due to extreme rarity of such cases."	3.72	Effect of risperidone on prolactinoma--a case report. ( Jiloha, RC; Mendhekar, DN; Srivastava, PK, 2004)
"This exploratory analysis was performed to compare the efficacy and tolerability of risperidone when added to two different mood stabilizers (lithium or valproate) for mania in bipolar disorder."	3.72	Risperidone plus lithium versus risperidone plus valproate in acute and continuation treatment of mania. ( Binder, C; Kusumakar, V; Riccardelli, R; Yatham, LN, 2004)
"Topiramate is a novel anticonvulsant agent with a broad spectrum mechanism of action, and recent clinical reports indicate that it may have mood stabilizing properties in bipolar disorder."	3.71	Topiramate as a mood stabilizer. ( Kasper, S; Letmaier, M; Schreinzer, D; Wolf, R, 2001)
"This large study provides additional evidence that risperidone is effective and well tolerated when combined with mood stabilizers in the treatment of bipolar disorder and schizoaffective disorder, bipolar type."	3.71	Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. ( Benabarre, A; Colom, F; Corbella, B; Fernández, A; Goikolea, JM; Martínez, G; Martínez-Arán, A; Reinares, M; Torrent, C; Vieta, E, 2001)
"We report a 5-case series in which risperidone use in usual or lower-than-usual doses was unexpectedly associated with amenorrhea."	3.70	Risperidone and associated amenorrhea: a report of 5 cases. ( Kim, L; Kim, YK; Lee, MS, 1999)
"This is a retrospective chart review of outpatients with the diagnosis of bipolar disorder (DSM-IV) treated with risperidone at a university center."	3.70	Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. ( Biederman, J; Frazier, JA; Kim, GS; Meyer, MC; Shapiro, S; Spencer, TJ; Wilens, TE; Wozniak, J, 1999)
"Patients displaying a moderate-to-marked response to risperidone were more likely to be younger; receive diagnoses of bipolar disorder or schizoaffective disorder, depressive type; and have a shorter duration of illness and shorter length of stay prior to risperidone treatment."	3.69	Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. ( Balistreri, TM; DePriest, M; Holtman, HM; Keck, PE; Kizer, DL; McElroy, SL; Strakowski, SM; Wilson, DR, 1995)
"To describe a case of neuroleptic malignant syndrome associated with risperidone."	3.69	Neuroleptic malignant syndrome and risperidone: a case report. ( Bonwick, RJ; Hopwood, MJ; Morris, PL, 1996)
"To test the hypothesis that, although typical neuroleptics are commonly used in the treatment of bipolar disorder, newer atypical antipsychotic agents, like risperidone, may be more effective and better-tolerated."	3.69	Acute treatment of bipolar disorder with adjunctive risperidone in outpatients. ( Baldassano, CF; Ghaemi, SN; Sachs, GS; Truman, CJ, 1997)
"Patients in the acute phase of mania were assigned into two parallel groups given either lithium (blood level of 0."	3.11	Efficacy and safety of palmitoylethanolamide as an adjunctive treatment for acute mania: A randomized, double-blind, placebo-controlled trial. ( Abedini, T; Akhondzadeh, S; Ardakani, MK; Ghannadi, F; Hosseyni, R; Moghaddam, HS; Talaei, A, 2022)
" No serious adverse event was reported."	2.84	A Randomized, Double-Blind Placebo-Controlled Trial on Effectiveness and Safety of Celecoxib Adjunctive Therapy in Adolescents with Acute Bipolar Mania. ( Akhondzadeh, S; Gholamian, F; Karkhaneh-Yousefi, MA; Khezri, R; Mohammadi, MR; Mohammadinejad, P; Mousavi, SY; Zeinoddini, A, 2017)
" The aims of this study were to investigate the effectiveness and adverse effects of LAIR in children and adolescents with conduct disorder, bipolar disorder, and schizophrenia."	2.84	Effectiveness, Adverse Effects and Drug Compliance of Long-Acting Injectable Risperidone in Children and Adolescents. ( Ceylan, MF; Cop, E; Erdogan, B; Tural Hesapcioglu, S, 2017)
"Average weight gain was 3."	2.82	Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial. ( Baruch, P; Beaulieu, S; Bond, DJ; da Cunha, A; Daigneault, A; Dias, R; Kapczinski, F; Kauer-Sant'Anna, M; Kunz, M; Lafer, B; Lam, RW; Milev, R; Parikh, SV; Qian, H; Quevedo, J; Schaffer, A; Sharma, V; Silverstone, PH; Walji, N; Wong, H; Yatham, LN; Young, LT, 2016)
" Safety measures included body mass index, serum prolactin, extrapyramidal adverse effects, and electrocardiogram."	2.80	Efficacy and Safety of Risperidone and Quetiapine in Adolescents With Bipolar II Disorder Comorbid With Conduct Disorder. ( Masi, G; Milone, A; Pisano, S; Stawinoga, A; Veltri, S, 2015)
"Risperidone was more efficacious than lithium or divalproex sodium for the initial treatment of childhood mania but had potentially serious metabolic effects."	2.77	A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. ( Axelson, DA; Birmaher, B; Bolhofner, K; Emslie, G; Geller, B; Joshi, P; Lavori, P; Luby, JL; Nusrat, N; Riddle, MA; Robb, A; Ryan, ND; Tillman, R; Vitiello, B; Wagner, KD; Walkup, JT; Wolf, DV, 2012)
"Risperidone was shown to have significant anti-manic effects which was observed as early as week 1, following start of treatment."	2.77	Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania. ( Hsu, MC; Kuo, CC; Ouyang, WC; Yeh, IN, 2012)
" During the double-blind period, dosing was fixed at patients' final open-label dose (25 mg, 66% of patients; 37."	2.77	A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. ( Cordoba, R; Huberlant, B; Martinez, L; Montgomery, S; Schreiner, A; Sulaiman, AH; Vieta, E, 2012)
"Co-morbid diagnoses, such as disruptive behavior disorders (DBDs) and high levels of aggression, are extremely common among youth with pediatric bipolar disorder (PBD) and may interfere with treatment response; however, they have rarely been examined as predictors of response to pharmacotherapy."	2.76	Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder. ( Celio, CI; Henry, D; Pavuluri, MN; Weinstein, SM; West, AE, 2011)
"Risperidone LAI was tolerable and no new safety concerns emerged compared with previous studies of risperidone LAI."	2.75	Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. ( Karcher, K; Kushner, S; Kusumakar, V; Palumbo, JM; Quiroz, JA; Yatham, LN, 2010)
"A population model was developed with the aim to simultaneously describe risperidone and 9-hydroxyrisperidone pharmacokinetics; to obtain estimates for pharmacokinetic parameters and associated inter- and intra-individual variability of risperidone and 9-hydroxyrisperidone; and to evaluate the influence of patient demographic characteristics and other factors on risperidone, 9-hydroxyrisperidone, and active moiety pharmacokinetics."	2.73	Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder. ( Ludwig, EA; Piotrovsky, V; Vermeulen, A, 2007)
" Considering the mean maximal dosage of 5."	2.73	Risperidone monotherapy in manic inpatients: an open label, multicentre trial. ( Amann, B; Dittmann, S; Forsthoff, A; Grunze, H; Hermle, L; Schäfer, M; Schmidt, F; Schreiner, A; Seemüller, F; Stampfer, R; Walden, J, 2007)
"Psychosis has been identified in as many as 68% of patients with bipolar mania."	2.73	Psychotic symptoms in patients with bipolar mania. ( Bossie, CA; Canuso, CM; Dunner, DL; Youssef, E; Zhu, Y, 2008)
"Olanzapine-treated patients had greater HAM-D-21 (p = ."	2.72	Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. ( Baker, RW; Brown, EB; Jamal, HH; Perlis, RH; Schuh, LM; Tohen, M; Zarate, CA, 2006)
"Risperidone monotherapy was significantly more efficacious than placebo in the treatment of acute mania and demonstrated a rapid onset of action."	2.71	Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. ( Canuso, C; Eerdekens, M; Grossman, F; Hirschfeld, RM; Karcher, K; Keck, PE; Kramer, M, 2004)
"Risperidone was generally well tolerated."	2.71	Risperidone in combination with mood stabilizers for acute mania: a multicentre, open study. ( Bahk, WM; Choi, SK; Kim, KS; Kim, YH; Lee, C; Lee, YH; Pae, CU; Song, HK; Yoon, JS, 2004)
" The aim of this study was to compare the effectiveness and tolerability of topiramate and divalproex in combination with risperidone for treating acute mania patients in a naturalistic treatment setting."	2.71	Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study. ( Bahk, WM; Choi, SK; Chung, SK; Jon, DI; Lee, JS; Pae, CU; Paik, IH; Shin, YC; Woo, JM; Yoon, BH, 2005)
"Risperidone was received by 146 patients and placebo by144."	2.71	Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. ( Eerdekens, M; Grossman, F; Khanna, S; Kramer, M; Lyons, B; Vieta, E, 2005)
"Risperidone was well tolerated; side effects were few and generally mild."	2.70	Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD). ( Benabarre, A; Colom, F; Fernández, A; Gastó, C; Herraiz, M; Martínez-Arán, A; Reinares, M; Vieta, E, 2001)
" It also appears that rapid dosage increases for antimanic treatment can cause potentially severe side effects."	2.69	Tiagabine appears not to be efficacious in the treatment of acute mania. ( Amann, B; Erfurth, A; Grunze, H; Marcuse, A; Normann, C; Walden, J, 1999)
" The effect size, remission/response rate, and risk for discontinuation due to adverse events (AEs), weight gain (WG), nervous systems and gastrointestinal AEs were assessed and compared between two regions with Cohen's d or number needed to treat/harm."	2.66	Do Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? ( Bai, Y; Chen, G; Gao, K; Yang, H, 2020)
" However, there are important limitations to the long-term use of depot typical neuroleptics in patients with bipolar disorder, including risk of extrapyramidal side effects and tardive dyskinesia, which may exceed that of patients with schizophrenia, and the potential for treatment-emergent exacerbation of depressive symptoms."	2.46	Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder. ( Bobo, WV; Shelton, RC, 2010)
"Schizophrenia is a chronic disorder, usually necessitating lifelong treatment."	2.45	Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness. ( Keith, S, 2009)
"Inflammation is closely linked with behavioral parameters such as exercise, sleep, alcohol abuse, and smoking, as well as with medical comorbidities including coronary artery disease, obesity and insulin resistance, osteoporosis, and pain."	2.45	Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. ( Goldstein, BI; Kemp, DE; McIntyre, RS; Soczynska, JK, 2009)
"Ten acute trials in mania, 3 in bipolar depression, and 8 in schizophrenia were identified, along with 2 maintenance studies in bipolar disorder and 2 in schizophrenia."	2.44	A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. ( Calabrese, JR; Gajwani, P; Ganocy, SJ; Gao, K; Kemp, DE; Muzina, DJ, 2008)
"Risperidone has also been reported to be useful in the longer-term treatment of bipolar disorder."	2.43	Risperidone for bipolar disorders. ( Aulakh, L; Fuller, MA; Keaton, DB; Madhusoodanan, S; Sajatovic, M, 2005)
"Risperidone (Risperdal) is an atypical antipsychotic with high affinity for 5-hydroxytryptamine (5-HT)2A, dopamine D2 and alpha1- and alpha2-adrenergic receptors."	2.43	Risperidone: a review of its use in the treatment of bipolar mania. ( Fenton, C; Scott, LJ, 2005)
"This does not extend to bipolar depression, however, good data is now emerging for some agents and will need to be considered for each individual agent as it accumulates."	2.43	A typical mood stabilizers: a "typical role for atypical antipsychotics. ( Berk, M; Bourin, M; Dodd, S; Ivanovski, B; Lagopoulos, J; Malhi, GS; Mitchell, PB, 2005)
"Risperidone monotherapy was more effective than placebo in reducing manic symptoms, using the Young Mania Rating Scale (YMRS) (weighted mean difference (WMD) -5."	2.43	Risperidone alone or in combination for acute mania. ( Bauer, MS; Geddes, GR; Gijsman, HJ; Goodwin, GM; Rendell, JM, 2006)
" Their adverse effects, which include extrapyramidal side effects, tardive dyskinesia, weight gain, sedation, and sexual dysfunction, often lead to non-compliance; their use may have a negative impact on the overall course of illness; and they may not be as effective as lithium in treating the core manic symptoms over the long term."	2.41	Antipsychotic drug side effect issues in bipolar manic patients. ( Zarate, CA, 2000)
" One general rule that may reduce the risks of toxic drug interactions is to add medication to the patient's current regimen in modest doses and increase the dose slowly."	2.40	Mood stabilizer combinations: a review of safety and efficacy. ( Freeman, MP; Stoll, AL, 1998)
"The effects of neuroleptics on bipolar depression need further study."	2.39	Antipsychotics in bipolar disorder. ( Gelenberg, AJ; Hopkins, HS, 1996)
"Use of antidepressants in bipolar depression is generally not recommended although it may be reasonable in specific clinical situations."	1.72	Pharmacologic treatment and management of bipolar disorder in adolescents. ( El-Mallakh, RS; Elsayed, OH; Pahwa, M, 2022)
"Lithium carbonate was associated with increased risks of rash (PT), drug interaction (PT), and tubulointerstitial diseases (SMQ)."	1.72	Analysis of adverse drug events in patients with bipolar disorders using the Japanese Adverse Drug Event Report database. ( Nabekura, T; Uwai, Y, 2022)
"Chronic risperidone did not reverse mania-like behavior in DAT knockdown mice."	1.62	Chronic antipsychotic treatment exerts limited effects on the mania-like behavior of dopamine transporter knockdown mice. ( Arnt, J; Bundgaard, C; Cope, ZA; Geyer, MA; Kenton, JA; Martin, MV; Minassian, A; Perry, W; van Enkhuizen, J; Young, JW, 2021)
"Hyperprolactinemia was found in 120 (70."	1.56	Prolactin response to antipsychotics: An inpatient study. ( Bredicean, CA; Dehelean, L; Dumitrascu, V; Papava, I; Romosan, AM; Romosan, RS; Ursoniu, S, 2020)
" We showed that chronic administration of risperidone did not affect the DNA methylation status at this CpG site using common marmosets, and that in vitro DNA methylation at this CpG site diminished the promoter activity of SLC6A4."	1.56	Promoter Activity-Based Case-Control Association Study on SLC6A4 Highlighting Hypermethylation and Altered Amygdala Volume in Male Patients With Schizophrenia. ( Abe, O; Asai, T; Bundo, M; Fukunaga, M; Hashimoto, R; Ikeda, M; Ikegame, T; Ishigooka, J; Iwamoto, K; Iwashiro, N; Iwata, N; Kakiuchi, C; Kasai, K; Kato, T; Kawamura, Y; Koike, S; Koshiyama, D; Murata, Y; Natsubori, T; Nishimura, F; Okada, N; Owada, K; Saito, T; Sasaki, T; Sugawara, H; Yamashita, F; Yamasue, H; Yoshikawa, A, 2020)
"Risperidone was given for ongoing delusions."	1.56	Manic episode in patient with bipolar disorder and recent multiple sclerosis diagnosis: A case report. ( Wichser, L; Yang, S, 2020)
"The aim of the study is to find a relationship between the individual intervariability of CYP2D6 and the incidence of hyperprolactinemia as side effect of atypical antipsychotics."	1.51	Impact of the CYP2D6 phenotype on hyperprolactinemia development as an adverse event of treatment with atypical antipsychotic agents in pediatric patients. ( Andreescu, N; Grădinaru, R; Nussbaum, L; Puiu, M; Suciu, L, 2019)
"Hypogonadotropic hypogonadism is a rare congenital disorder characterised by the deficiency and the absence of puberty and infertility."	1.48	Rare cause of manic period trigger in bipolar mood disorder: testosterone replacement. ( Elboga, G; Sayiner, ZA, 2018)
"Risperidone monotherapy was the primary antipsychotic treatment."	1.43	Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes. ( Badner, JA; Bishop, JR; Harris, MS; Keshavan, MS; Nimgaonkar, VL; Patel, SR; Prasad, KM; Reilly, JL; Stevenson, JM; Sweeney, JA; Weiden, PJ, 2016)
" The objective of the study was to identify pharmacokinetic interactions of different mood stabilizers on the metabolism of risperidone (RIS) under natural conditions."	1.43	Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment. ( Gründer, G; Haen, E; Hiemke, C; Lammertz, SE; Paulzen, M; Schoretsanitis, G; Schruers, KR; Stegmann, B, 2016)
"Alcohol withdrawal delirium is associated with significant morbidity and mortality."	1.42	Alcohol withdrawal delirium manifested by manic symptoms in an elderly patient. ( Chan, HY; Lee, KI, 2015)
"A 23-year-old man had unilateral rubral tremors as a result of a midbrain lesion plus risperidone exposure for treatment of manic symptoms."	1.35	Unilateral rubral tremor following treatment with risperidone. ( Shen, YC, 2009)
"The child was diagnosed with Tourette's syndrome at 7 years of age when he suffered from tics and experienced his first manic episode."	1.35	Diagnosis and treatment of comorbidities of Tourette's syndrome and bipolar disorder in a 10-year-old boy. ( Huang, MF; Huang, RR; Wang, PW; Yen, CF, 2009)
"In the treatment of bipolar and manic disorders, risperidone and olanzapine were associated with a higher risk for hospitalization than quetiapine, and possibly ziprasidone."	1.34	Hospitalization risks in the treatment of bipolar disorder: comparison of antipsychotic medications. ( Gianfrancesco, F; Goldberg, JF; Rajagopalan, K; Wang, RH, 2007)
"Risperidone monotherapy treatment was associated with hyperprolactinaemia in 69% of patients ( n = 35) and in 100% of female patients (n = 16) and amisulpride monotherapy in 100% (n = 7)."	1.34	Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. ( Bushe, C; Shaw, M, 2007)
"Risperidone was switched to another antipsychotic."	1.34	Risperidone-induced polydipsia and polyphagia associated with galactorrhea, abdominal pain, and rapid weight gain in an adolescent Hispanic female. ( Afzal, KI; Briones, DF; DeVargas, C, 2007)
"We accepted him as type 1 diabetes mellitus (DM type 1)."	1.33	Risperidone-associated transient diabetic ketoacidosis and diabetes mellitus type 1 in a patient treated with valproate and lithium. ( Alpaslan, T; Bulent, C; Cengiz, T; Mithat, B, 2005)
"The authors report 2 cases, in Alzheimer's disease and vascular dementia, in which erotomania emerged in the early stage of the underlying disorder."	1.32	Erotomania variants in dementia. ( Brüne, M; Schröder, SG, 2003)
"Existing treatment options for bipolar depression include lithium, lamotrigine and conventional antidepressants."	1.32	Bipolar depression: the role of atypical antipsychotics. ( Calabrese, JR; Post, RM, 2004)
"Previous reports document visual illusions resembling hallucinogen persisting perception disorder (HPPD) after risperidone treatment in patients with histories of previous LSD exposure."	1.31	Posthallucinogen-like visual illusions (palinopsia) with risperidone in a patient without previous hallucinogen exposure: possible relation to serotonin 5HT2a receptor blockade. ( Abdelhamid, A; Annandale, JB; Lauterbach, EC, 2000)
"Converging evidence indicates that, in controlled drug trials, individuals receiving novel antipsychotic medications have fewer adverse effects than those receiving conventional antipsychotic medications."	1.31	Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study. ( Bromet, EJ; Davidson, M; Rabinowitz, J, 2001)
"Psychopharmacology research aims to expand the therapeutic ratio between efficacy, on the one hand, and adverse events and safety, on the other."	1.31	Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. ( McIntyre, RS, 2002)
" A full pharmacokinetic time profile of lithium was obtained."	1.31	Bayesian pharmacokinetics of lithium after an acute self-intoxication and subsequent haemodialysis: a case report. ( Beijnen, JH; Kerbusch, T; Mathôt, RA; Meesters, EW; Otten, HM; Schellens, JH; van Kan, HJ, 2002)

Research

Studies (383)

Authors

Clinical Trials (29)

Trial Overview

Trial Outcomes

Sedation Score

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	53 (13.84)	18.2507
2000's	188 (49.09)	29.6817
2010's	119 (31.07)	24.3611
2020's	23 (6.01)	2.80

Authors	Studies
Shahid, M	1
Walker, GB	1
Zorn, SH	1
Wong, EH	1
Nestsiarovich, A	1
Gaudiot, CES	1
Baldessarini, RJ	1
Vieta, E	16
Zhu, Y	3
Tohen, M	8
Kishi, T	2
Ikuta, T	1
Matsuda, Y	1
Sakuma, K	1
Okuya, M	1
Nomura, I	1
Hatano, M	1
Iwata, N	4
Gomes, FA	1
Cerqueira, RO	1
Lee, Y	1
Mansur, RB	1
Kapczinski, F	2
McIntyre, RS	6
Yatham, LN	17
Berk, M	4
Milev, R	2
Brietzke, E	2
Kessing, LV	1
Wozniak, J	5
DiSalvo, M	1
Farrell, A	1
Yule, A	1
Joshi, G	1
Cook, E	1
Faraone, SV	2
Biederman, J	5
Elsayed, OH	1
Pahwa, M	1
El-Mallakh, RS	1
Abedini, T	1
Hosseyni, R	1
Ghannadi, F	1
Moghaddam, HS	2
Ardakani, MK	1
Talaei, A	1
Akhondzadeh, S	3
Ikeda, M	3
Saito, T	3
Kanazawa, T	1
Uwai, Y	1
Nabekura, T	1
Yu, CL	1
Carvalho, AF	1
Thompson, T	1
Tsai, TC	1
Tseng, PT	1
Hsu, CW	1
Hsu, TW	1
Liang, CS	2
Bai, Y	1
Chen, G	1
Yang, H	2
Gao, K	4
Bahmani, S	1
Bayanati, S	1
Mahdavinasa, M	1
Rezaei, F	1
Dehelean, L	1
Romosan, AM	1
Papava, I	1
Bredicean, CA	1
Dumitrascu, V	1
Ursoniu, S	1
Romosan, RS	1
Um, YH	1
Kim, TW	1
Seo, HJ	1
Hong, SC	1
Kim, SM	1
Oh, JH	1
Jeong, JH	1
Goldberg, JF	3
Ikegame, T	2
Bundo, M	2
Okada, N	1
Murata, Y	2
Koike, S	1
Sugawara, H	2
Owada, K	1
Fukunaga, M	1
Yamashita, F	1
Koshiyama, D	1
Natsubori, T	1
Iwashiro, N	1
Asai, T	1
Yoshikawa, A	2
Nishimura, F	2
Kawamura, Y	2
Ishigooka, J	1
Kakiuchi, C	2
Sasaki, T	2
Abe, O	1
Hashimoto, R	1
Yamasue, H	1
Kato, T	2
Kasai, K	2
Iwamoto, K	2
Hassoun, Y	1
Sureddi, S	1
Tünel, M	1
Çakmak, S	1
Tamam, L	1
Demir, T	1
Escudero, MAG	1
Gutiérrez-Rojas, L	2
Lahera, G	1
Yang, S	1
Wichser, L	1
Koh, LC	1
Chandwani, N	1
Lim, S	1
Chan, CYW	1
Cope, ZA	1
Kenton, JA	1
Minassian, A	1
Martin, MV	1
Perry, W	1
Bundgaard, C	1
Arnt, J	1
van Enkhuizen, J	1
Geyer, MA	1
Young, JW	1
Veraart, JKE	1
Smith-Apeldoorn, SY	1
Bakker, IM	1
Visser, BAE	1
Kamphuis, J	1
Schoevers, RA	1
Touw, DJ	1
Hodkinson, A	1
Heneghan, C	1
Mahtani, KR	1
Kontopantelis, E	1
Panagioti, M	1
Mousavi, SY	1
Khezri, R	1
Karkhaneh-Yousefi, MA	1
Mohammadinejad, P	1
Gholamian, F	1
Mohammadi, MR	1
Zeinoddini, A	1
Hsieh, MH	2
Chuang, PY	1
Wu, CS	2
Chang, CJ	2
Chung, PF	1
Tang, CH	2
Weiser, M	1
Levi, L	1
Levine, SZ	1
Bialer, M	2
Shekh-Ahmad, T	1
Matei, V	1
Tiugan, A	1
Cirjaliu, D	1
Sava, C	1
Sinita, E	1
Zamora, D	1
Davis, JM	2
Ceylan, MF	1
Erdogan, B	1
Tural Hesapcioglu, S	1
Cop, E	1
Young, RC	1
Mulsant, BH	1
Sajatovic, M	4
Gildengers, AG	1
Gyulai, L	2
Al Jurdi, RK	1
Beyer, J	1
Evans, J	1
Banerjee, S	1
Greenberg, R	1
Marino, P	1
Kunik, ME	1
Chen, P	1
Barrett, M	1
Schulberg, HC	1
Bruce, ML	1
Reynolds, CF	1
Alexopoulos, GS	1
Fjukstad, KK	1
Engum, A	1
Lydersen, S	1
Dieset, I	1
Steen, NE	1
Andreassen, OA	1
Spigset, O	1
Joshi, K	1
Mao, L	2
Biondi, DM	1
Millet, R	1
Sawamura, R	1
Shimanaga, S	1
Takeoka, Y	1
Hashimoto, M	1
Lähteenvuo, M	1
Tanskanen, A	1
Taipale, H	1
Hoti, F	1
Vattulainen, P	1
Tiihonen, J	1
Augusto, M	1
Greene, M	2
Touya, M	2
Sweeney, SM	1
Waters, H	1
Dean, B	1
Gibbons, A	1
Gogos, A	1
Udawela, M	1
Thomas, E	1
Scarr, E	1
Elboga, G	1
Sayiner, ZA	1
Yan, T	1
Chang, E	1
Broder, MS	1
Robinson, DG	1
Gallego, JA	2
John, M	1
Hanna, LA	1
Zhang, JP	1
Birnbaum, ML	1
Greenberg, J	1
Naraine, M	1
Peters, BD	1
McNamara, RK	1
Malhotra, AK	1
Szeszko, PR	1
Dias Alves, M	1
Micoulaud-Franchi, JA	1
Simon, N	1
Vion-Dury, J	1
Chhatlani, A	1
Farheen, SA	1
Setty, MJ	1
Tampi, RR	1
Grădinaru, R	1
Andreescu, N	1
Nussbaum, L	1
Suciu, L	1
Puiu, M	1
Valdes, M	1
Bertolin, S	1
Qian, H	2
Wong, H	2
Lam, RW	5
Keramatian, K	1
Chakrabarty, T	1
Schmidt, M	1
Sofronescu, A	1
Short, B	1
Nahas, Z	1
Samalin, L	1
Nourry, A	1
Charpeaud, T	1
Llorca, PM	1
Buoli, M	1
Serati, M	1
Altamura, AC	1
Ersoz Alan, B	1
Unal, D	1
Hooshmand, F	1
Miller, S	1
Dore, J	1
Wang, PW	2
Hill, SJ	1
Portillo, N	1
Ketter, TA	3
Lu, YY	1
Hsueh, JH	1
Wei, IH	1
Huang, CC	1
Moss, MC	1
Kozlowski, T	1
Dupuis, R	1
Detwiler, R	1
Lee, RM	1
Deyo, JC	1
Chatterjee, B	1
Sharan, P	1
Taylor, DM	1
Cornelius, V	1
Smith, L	1
Young, AH	1
Wang, D	1
Li, Q	1
Favis, R	1
Jadwin, A	1
Chung, H	1
Fu, DJ	1
Savitz, A	1
Gopal, S	2
Cohen, N	1
Moosavi, SM	1
Ahmadi, M	1
Monajemi, MB	1
Chuang, WC	1
Chen, CY	1
Kuo, SC	1
Chen, TY	1
Yeh, YW	1
Chan, HY	1
Lee, KI	1
Marston, L	1
Nazareth, I	1
Petersen, I	1
Walters, K	1
Osborn, DP	1
Chen, KJ	1
Lu, ML	1
Shen, WW	1
Bonaccorso, S	3
Sodhi, M	1
Li, J	1
Bobo, WV	4
Chen, Y	2
Tumuklu, M	1
Theleritis, C	1
Jayathilake, K	3
Meltzer, HY	3
Kowatch, RA	3
Scheffer, RE	1
Monroe, E	1
Delgado, S	1
Altaye, M	1
Lagory, D	1
Granstein, J	1
Strimbu, K	1
Francois, D	1
Kahn, DA	1
Masi, G	1
Milone, A	1
Stawinoga, A	1
Veltri, S	1
Pisano, S	1
Wlodarczyk, BJ	1
Ogle, K	1
Lin, LY	1
Finnell, RH	1
Beaulieu, S	1
Schaffer, A	1
Kauer-Sant'Anna, M	2
Lafer, B	3
Sharma, V	1
Parikh, SV	2
Daigneault, A	1
Bond, DJ	5
Silverstone, PH	1
Walji, N	1
Baruch, P	1
da Cunha, A	1
Quevedo, J	1
Dias, R	1
Kunz, M	2
Young, LT	2
Koplewicz, HS	1
Salpekar, JA	2
Joshi, PT	2
Axelson, DA	5
Reinblatt, SP	1
Yenokyan, G	3
Sanyal, A	2
Walkup, JT	5
Vitiello, B	5
Luby, JL	3
Wagner, KD	5
Nusrat, N	2
Riddle, MA	5
Miller, L	1
Robb, A	4
Wolf, D	1
Birmaher, B	4
Cawkwell, P	1
Lawler, A	1
Maneta, E	1
Coffey, BJ	1
Stevenson, JM	1
Reilly, JL	1
Harris, MS	1
Patel, SR	1
Weiden, PJ	1
Prasad, KM	1
Badner, JA	1
Nimgaonkar, VL	1
Keshavan, MS	1
Sweeney, JA	6
Bishop, JR	2
Perna, G	1
Alessandra, A	1
Raffaele, B	1
Elisa, M	1
Giuseppina, D	1
Paolo, C	1
Maria, N	1
Daniela, C	1
Lim, CH	1
Zainal, NZ	1
Kanagasundram, S	1
Zain, SM	1
Mohamed, Z	1
Patel, E	1
Mennella, C	1
Dickstein, DP	2
Chan, HW	1
Huang, CY	1
Feng, WJ	1
Yen, YC	1
Schoretsanitis, G	1
Haen, E	1
Gründer, G	1
Stegmann, B	1
Schruers, KR	1
Hiemke, C	1
Lammertz, SE	1
Paulzen, M	1
Fang, F	1
Wang, Z	1
Wu, R	1
Calabrese, JR	6
Ryan, PB	1
Schuemie, MJ	1
Ramcharran, D	1
Stang, PE	1
Önen, Ö	1
Kutlu, A	1
Erkuran, HÖ	1
Oldham, J	1
MacMillan, CM	1
Withney, JE	1
Korndörfer, SR	1
Tilley, CA	1
Mrakotsky, C	1
Gonzalez-Heydrich, JM	1
Chang, KD	1
Croarkin, PE	1
Emslie, GJ	1
Mayes, TL	1
Shen, YC	1
Nieto, E	1
Autet, A	1
Rosa, AR	1
Goikolea, JM	7
Cruz, N	1
Bonet, P	1
Jon, DI	3
Bahk, WM	6
Yoon, BH	3
Shin, YC	2
Cho, HS	2
Lee, E	1
Ha, K	1
Kim, W	1
Chung, SK	3
Seo, JS	2
Min, KJ	2
Nejtek, VA	1
Avila, M	1
Chen, LA	1
Zielinski, T	1
Djokovic, M	1
Podawiltz, A	1
Kaiser, K	1
Bae, S	1
Rush, AJ	1
Sheehan, DV	2
McElroy, SL	5
Harnett-Sheehan, K	1
Keck, PE	7
Janavs, J	1
Rogers, J	1
Gonzalez, R	1
Shivakumar, G	1
Suppes, T	2
Keith, S	1
Boarati, MA	2
Castillo, AR	1
Castillo, JC	1
Fu-I, L	2
Moncrieff, J	1
Cohen, D	1
Mason, JP	1
Silva, R	1
Thapa, R	1
Biswas, B	1
Takahashi, T	1
Wood, SJ	1
Yung, AR	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Acute Pharmacotherapy of Late-Life Mania (GERI-BD)[NCT00254488]	Phase 4	224 participants (Actual)	Interventional	2005-11-30	Completed
Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations[NCT01181960]		1,066 participants (Actual)	Observational	2010-08-31	Completed
The Effects of Short-term Lithium Administration on Striatal Reward Processing and Prefrontal Control During Reappraisal in Healthy Volunteers[NCT03965247]		37 participants (Actual)	Interventional	2011-10-31	Completed
Detecting Which Patients With Schizophrenia Will Improve With Omega-3 Treatment[NCT01786239]		50 participants (Actual)	Interventional	2013-05-31	Completed
Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders[NCT00221403]	Phase 3	46 participants (Actual)	Interventional	2004-09-30	Completed
Placebo Controlled Trial of Valproate Versus Risperidone in Young Children With Bipolar Disorder[NCT02456454]	Phase 3	46 participants (Actual)	Interventional	2006-01-31	Completed
Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode[NCT01977300]	Phase 3	159 participants (Actual)	Interventional	2003-01-31	Completed
Treatment of Early Age Mania (TEAM) Study[NCT00057681]	Phase 3	379 participants (Actual)	Interventional	2003-02-28	Completed
A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder Outpatients With Current Stimulant Dependence[NCT00227123]		96 participants (Actual)	Interventional	2002-10-31	Completed
A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder[NCT00277654]	Phase 3	111 participants (Actual)	Interventional	2004-02-29	Completed
The Safety and Effectiveness of Probiotic Supplementation on Bipolar Depression: a Proof of Concept Randomized Controlled Trial[NCT02155972]	Phase 2	16 participants (Actual)	Interventional	2013-05-31	Terminated (stopped due to The trial was terminated because of inability to recruit the needed number of participants)
A Prospective, Randomized, Double-blind, Placebo-controlled Study of the Effectiveness and Safety of RISPERDAL CONSTA Augmentation in Adult Patients With Frequently-relapsing Bipolar Disorder[NCT00094926]	Phase 3	275 participants (Actual)	Interventional	2004-05-31	Completed
A Randomized, Double-blind, Placebo-controlled Study to Explore the Efficacy and Safety of Risperidone Long-acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar 1 Disorder, With Open-label Extension[NCT00132678]	Phase 3	559 participants (Actual)	Interventional	2005-02-28	Completed
Effects of Risperidone and Olanzapine on Weight Gain, Physical Health, and Outcome in a Community Sample of Severity and Persistently Ill Patients[NCT00179062]		300 participants (Actual)	Interventional	2000-02-29	Completed
Controlled Trial of Risperidone and Divalproex Sodium With MRI Assessment of Affected Circuitry in Pre and Post Treatment in Pediatric Bipolar[NCT00176202]	Phase 3	65 participants (Actual)	Interventional	2003-04-30	Completed
Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo[NCT00088036]	Phase 3	450 participants	Interventional	2004-02-29	Completed
Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder[NCT00094549]	Phase 4	500 participants	Interventional	2004-10-31	Completed
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features[NCT00035321]	Phase 3	600 participants	Interventional	2002-04-30	Completed
Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Flexible Dose Double-Blind Comparison With Placebo[NCT00091650]	Phase 3	300 participants	Interventional	2004-03-31	Completed
The Safety And Efficacy Of Risperdal� (Risperidone) Versus Placebo As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder[NCT00250367]	Phase 3	151 participants (Actual)	Interventional	1997-10-31	Completed
The Efficacy And Safety Of Flexible Dosage Ranges Of Risperidone Versus Placebo In The Treatment Of Manic Episodes Associated With Bipolar I Disorder.[NCT00257075]	Phase 3	267 participants (Actual)	Interventional	2000-12-31	Completed
The Efficacy And Safety Of Flexible Dose Ranges Of Risperidone Versus Placebo Or Haloperidol In The Treatment Of Manic Episodes Associated With Bipolar I Disorder.[NCT00253162]	Phase 3	439 participants (Actual)	Interventional	2001-03-31	Completed
Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions[NCT02292056]		50 participants (Anticipated)	Interventional	2013-09-30	Recruiting
Aripiprazole for Pre-Existing Neuroleptic-Induced Tardive Dyskinesia: a Prospective 26-Week Observational Study[NCT00837707]	Phase 4	25 participants (Anticipated)	Interventional	2008-06-30	Recruiting
The Efficacy And Safety Of Flexible Dosage Ranges Of Risperidone Versus Placebo In The Treatment Of Manic Or Mixed Episodes Associated With Bipolar I Disorder[NCT00249236]	Phase 3	291 participants (Actual)	Interventional	2001-03-31	Completed
Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)[NCT00012558]		5,000 participants	Interventional	1998-09-30	Completed
Differences in Cognitive Function Due to Acute Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Out-Patients.[NCT00097032]	Phase 3	30 participants (Actual)	Interventional	2004-10-31	Completed
Treatment and Outcome of Early Onset Bipolar Disorder[NCT00048802]	Phase 4	40 participants	Interventional	2002-08-31	Completed
The Safety And Efficacy Of Risperdal� (Risperidone) Versus Placebo Versus Haloperidol As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder[NCT00253149]	Phase 3	158 participants (Actual)	Interventional		Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The Sedation Item score of the UKU (Norwegian for Committee of Clinical Investigations) Side Effect Rating Scale. A higher value indicates greater severity. Range is 0-3 (not present, mild, moderate, or severe). (NCT00254488)
Timeframe: Day 4, Day 9, Day 15, and then Weekly from Week 3 to Week 9

Young Mania Rating Scale (YMRS) Scores

Intervention	units on a scale (Mean)
	Day 4	Day 9	Day 15	Week 3	Week 4	Week 5	Week 6	Week 7	Week 8	Week 9
Divalproex (DV)	0.5	0.6	0.5	0.6	0.5	0.4	0.5	0.4	0.3	0.4
Lithium (LI)	0.5	0.6	0.4	0.5	0.5	0.5	0.5	0.4	0.4	0.4

The Young Mania Rating Scale is an eleven item interviewer-rated instrument. Four items are scored 0-8, the others 0-4. The total score therefore ranges from 0-60, with higher values reflecting greater severity. (NCT00254488)
Timeframe: Day 4, Day 9, Day 15, and then Weekly from Week 3 to Week 9

Treatment Response

Intervention	units on a scale (Mean)
	Day 4	Day 9	Day 15	Week 3	Week 4	Week 5	Week 6	Week 7	Week 8	Week 9
Divalproex (DV)	19.7	16.3	15.2	13.1	9.9	9.8	8.2	7.0	6.7	6.8
Lithium (LI)	21.4	19.0	14.3	12.1	9.4	7.6	7.2	6.0	6.0	6.3

The primary outcome measure will be the total Brief Psychiatric Rating Scale Score. The range of the BPRS is 0 to 126 with higher scores indicated more psychological symptoms. (NCT01786239)
Timeframe: 16 weeks

YMRS

Intervention	units on a scale (Least Squares Mean)
	Baseline BPRS Score	Week 16 BPRS Score
Omega-3 Capsules & Risperidone	41.64	22.5868
Placebo & Risperidone	42.38	27.2235

Young Mania Rating Scale (YMRS) total scores change from baseline by treatment group. The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in manic symptoms. (NCT00221403)
Timeframe: 6 weeks

Clinical Global Impressions-Bipolar Mania Improvement

Intervention	score on a scale (Least Squares Mean)
Valproate (VPA)	10
Risperidone	18.82
Placebo	4.29

The Clinical Global Impressions-Bipolar (CGI-BP) assessment instrument measured improvement in mania, depression, and overall bipolar illness. The primary outcome measure was mania improvement, which measured the change in mania from baseline. Scores were 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. (NCT00057681)
Timeframe: Measured at Week 8

K-SADS Mania Rating Scale

Intervention	units on a scale (Mean)
Randomized Medication - Lithium	2.49
Randomized Medication - Divalproex Sodium	2.73
Randomized Medication - Risperidone	1.70

The K-SADS Mania Rating Scale (KMRS) is comprised of 15 items modified from WASH-U-KSADS items. The individual items are scored on a 1-6 severity scale and then these item scores are summed to create an overall KMRS score. Guidelines for interpretation are as follows: 0-11 = no or minimal mania, 12-17 = mild mania, 18-25 = moderate mania, 26+ = marked or worse mania. The maximum possible score is 64. (NCT00057681)
Timeframe: Measured at Week 8

Modified Side Effects Form for Children and Adolescents

Intervention	units on a scale (Mean)
Randomized Medication - Lithium	24.06
Randomized Medication - Divalproex Sodium	26.31
Randomized Medication - Risperidone	14.58

The Modified Side Effects Form for Children and Adolescents includes 62 potential side effects, with measures of frequency and severity for each item. Frequencies are 0=not present, 1=1-2 days, 2=3-4 days, 3=5-7 days. Severity scores are 0=not present, 1=mild (does not interfere with functioning), 2=moderate (some interference with functioning), 3=severe (functioning is significantly impaired because of side effects). Items for cardiovascular, gastrointestinal, central nervous system, ocular, mouth and nose, genito urinary, dermatology, musculo-skeletal, and other side effects are included. For analyses, side effects that were reported at any frequency and a severity of 2 or greater were considered present. (NCT00057681)
Timeframe: Measured at Week 8

Change in Montgomery-Åsberg Depression Rating Scale (MADRS)

Intervention	side effects at week 8 (Mean)
Randomized Medication - Lithium	5.11
Randomized Medication - Divalproex Sodium	4.95
Randomized Medication - Risperidone	3.70

Measure of depression; score range 0 to 60 (lower score = less severity) (NCT00132678)
Timeframe: Baseline and Endpoint (last observation carried forward) of 24 month Double-Blind Period IV

Change in Young Mania Rating Scale (YMRS) Scores.

Intervention	units on a scale (Mean)
RISPERDAL CONSTA	2.8
Placebo	4.9

Measure of mania; score range 0 to 60 (lower score = less severity) (NCT00132678)
Timeframe: Baseline and Endpoint (last observation carried forward) of 24 month Double-Blind Period IV

Number of Participants Who Had a Mood Relapse.

Intervention	units on a scale (Mean)
RISPERDAL CONSTA	2.9
Placebo	9.1

"Mood Relapse was defined as:~The subject met DSM-IV criteria for a manic, hypomanic, mixed, or depressive episode; or, the subject needed treatment intervention with any mood stabilizer, antipsychotic medication (other than study drug), benzodiazepine (beyond the dosage allowed), or antidepressant medication; or the subject required hospitalization for any bipolar mood episode; or the subject had a YMRS or MADRS score >12 or a CGI-S score >4; or a dose increase, or supplementation with oral risperidone or another antipsychotic or mood stabilizer, was needed in the opinion of the investigator." (NCT00132678)
Timeframe: 24 months

Child Depression Rating Scale- Revised (CDRS-R)

Intervention	Participants (Number)
	Relapsed	Not Relapsed
Placebo	76	59
RISPERDAL CONSTA	42	98

Response for depressive symptoms was defined as a score less than 40 on the CDRS-R. Range is 18 to 120. Score 18 is normal and higher score signifies depression. The Children's Depression Rating Scale (CDRS) is a 16-item measure used to determine the severity of depression in children 6-18 years of age. Items are measured on 3-, 4-, 5-, and 6-point scales. The mean and standard deviation are measured in this study to illustrate outcome at baseline and when the subject ended the study. (NCT00176202)
Timeframe: Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point).

Child Mania Rating Scale (CMRS)

Intervention	units on a scale (Mean)
	Baseline	Last Observation Carried Forward (p<.01)
Divalproex	40.76	35.76
Risperidone	41.72	25.88

Child Mania rating scale is a parent rated measure to screen for symptoms of mania. It includes 21 items reflecting the DSM-IV criteria for a manic episode. Each item is answered on a four-point Likert type scale anchored by 0 (Never/Rare), 1 (Sometimes), 2 (Often), and 3 (Very Often). Maximum score possible is 63. Score higher than 20 is considered clinically significant, and this is a dimensional score of manic severity. (NCT00176202)
Timeframe: Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point).

Clinical Global Improvement in Bipolar Disorder Overall (CGI-BP Overall)

Intervention	units on scale (Mean)
	Baseline	LOCF
Divalproex Sodium	28.0	19.20
Risperidone	30.84	16.35

Severity of Illness and Global Improvement are rated on a 7-point scale by the clinician. In addition to rating the overall illness with the CGI-BP, severity and improvement are considered on various other dimensions such as mania, depression, attention deficit/hyperactivity, psychosis, aggression and sleep difficulties. Score of 1, 2 and 3 would mean there is clinically observed symptom improvement where 1 is the best outcome than 2 or 3. The point 4 is the point where the subject presents at baseline of that specific individual. If they become worse on clinical symptoms, they are rated as 5, 6 or 7 where 7 is worse than 5. (NCT00176202)
Timeframe: Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point).

Young Mania Rating Scale (YMRS)

Intervention	units on a scale (Mean)
	Baseline	LOCF
Divalproex Sodium	4.37	2.97
Risperidone	4.80	2.77

This measure has 11 items. The purpose of each item is to rate the severity of that abnormality in the patient. A severity rating is assigned to each of the eleven items, based on the patient's subjective report of his or her condition over the previous forty-eight hours and the clinician's behavioral observations during the interview, with the emphasis on the latter. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. Total score of zero to 60 is possible, zero being normal and 60 being severe, 12 serving as a cut off point for illness if equal or above. There are several ways to show change in outcome. We show the mean and standard deviation at week 0 and 6. (NCT00176202)
Timeframe: Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point).

Article	Year
Preventing new episodes of bipolar disorder in adults: Systematic review and meta-analysis of randomized controlled trials. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2022, Volume: 54 Topics: Adult; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Lithium; Olanz	2022
Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. Molecular psychiatry, 2022, Volume: 27, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Carbamazepine; Female;	2022
What not to use in bipolar disorders: A systematic review of non-recommended treatments in clinical practice guidelines. Journal of affective disorders, 2022, 02-01, Volume: 298, Issue:Pt A Topics: Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Humans; Lamotrigine; Risperidone	2022
Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia. BMJ mental health, 2023, Volume: 26, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Haloperidol; Humans; Mania; Olanzapine; Quetia	2023
Do Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? Journal of affective disorders, 2020, 01-15, Volume: 261 Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Bipolar Disorder; Female; Humans; North Ame	2020
Second Generation Antipsychotics Monotherapy as Maintenance Treatment for Bipolar Disorder: a Systematic Review of Long-Term Studies. The Psychiatric quarterly, 2020, Volume: 91, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Humans; Olanzapine; Quetiapin	2020
Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. The international journal of neuropsychopharmacology, 2021, 10-23, Volume: 24, Issue:10 Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Depressio	2021
Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports. BMC medicine, 2021, 08-25, Volume: 19, Issue:1 Topics: Antipsychotic Agents; Bipolar Disorder; Humans; Male; Paliperidone Palmitate; Risperidone; Schizophr	2021
Use of cariprazine in psychiatric disorders: A systematic review. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2018, Volume: 30, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder; Humans; Piperazines; Risp	2018
Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review. CNS drugs, 2019, Volume: 33, Issue:5 Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Delayed-Action Preparations; Humans; Medicatio	2019
What is the evidence for the use of second-generation antipsychotic long-acting injectables as maintenance treatment in bipolar disorder? Nordic journal of psychiatry, 2014, Volume: 68, Issue:4 Topics: Antipsychotic Agents; Bipolar Disorder; Delayed-Action Preparations; Evidence-Based Medicine; Humans	2014
Is the combination of a mood stabilizer plus an antipsychotic more effective than mono-therapies in long-term treatment of bipolar disorder? A systematic review. Journal of affective disorders, 2014, Volume: 152-154 Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipola	2014
Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta psychiatrica Scandinavica, 2014, Volume: 130, Issue:6 Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder;	2014
Is There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA Guidelines. International journal of molecular sciences, 2016, 04-13, Volume: 17, Issue:4 Topics: Antipsychotic Agents; Bipolar Disorder; Humans; Panic Disorder; Piperazines; Quetiapine Fumarate; Ri	2016
Is there a 'weight neutral' second-generation antipsychotic for bipolar disorder? Expert review of neurotherapeutics, 2017, Volume: 17, Issue:4 Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Olanzapine; Risperidone	2017
The use of atypical antipsychotics in pediatric bipolar disorder. The Journal of clinical psychiatry, 2008, Volume: 69 Suppl 4 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders;	2008
Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. The Journal of clinical psychiatry, 2008, Volume: 69, Issue:7 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Child; Child, Pre	2008
Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness. Expert review of neurotherapeutics, 2009, Volume: 9, Issue:1 Topics: Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; Cost-Benefit Analysis; Delayed-Act	2009
Bipolar disorder. BMJ clinical evidence, 2007, Aug-01, Volume: 2007 Topics: Acute Disease; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; H	2007
Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. The Journal of clinical psychiatry, 2009, Volume: 70, Issue:8 Topics: Anti-Inflammatory Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Brief Psychiatric	2009
Long-acting risperidone: a review of its role in the treatment of bipolar disorder. Advances in therapy, 2009, Volume: 26, Issue:6 Topics: Antipsychotic Agents; Bipolar Disorder; Delayed-Action Preparations; Humans; Injections, Intramuscul	2009
Risperidone long-acting injection: in bipolar I disorder. Drugs, 2010, May-28, Volume: 70, Issue:8 Topics: Antipsychotic Agents; Bipolar Disorder; Chemotherapy, Adjuvant; Clinical Trials as Topic; Delayed-Ac	2010
Risperidone long-acting injection as monotherapy and adjunctive therapy in the maintenance treatment of bipolar I disorder. Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:10 Topics: Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Combination; Humans; Injections; Risperidone	2010
Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder. Expert review of neurotherapeutics, 2010, Volume: 10, Issue:11 Topics: Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; Drug Administration Schedule; Huma	2010
Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder. CNS drugs, 2012, May-01, Volume: 26, Issue:5 Topics: Antipsychotic Agents; Bipolar Disorder; Delayed-Action Preparations; Drug Approval; Humans; Injectio	2012
Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. Journal of affective disorders, 2013, Jan-25, Volume: 144, Issue:3 Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disord	2013
Pharmacotherapy of bipolar disorder: the role of atypical antipsychotics and experimental strategies. Human psychopharmacology, 2002, Volume: 17, Issue:8 Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Calcium Channel Blockers; Clozapine; Dibenz	2002
Safety in treating bipolar disorder. The Journal of family practice, 2003, Volume: Suppl Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Diabetes Melli	2003
Alternatives to lithium and divalproex in the maintenance treatment of bipolar disorder. Bipolar disorders, 2003, Volume: 5, Issue:3 Topics: Acetates; Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar	2003
[Treatment of acute bipolar disorder. Intriguing balancing act between mania and depression]. MMW Fortschritte der Medizin, 2003, May-26, Volume: 145 Suppl 2 Topics: Acute Disease; Algorithms; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiaze	2003
Pharmacologic management of psychosis in the elderly: a critical review. Journal of geriatric psychiatry and neurology, 2003, Volume: 16, Issue:4 Topics: Aged; Alzheimer Disease; Benzodiazepines; Bipolar Disorder; Clozapine; Depressive Disorder; Drug Adm	2003
Pharmacotherapy of bipolar II disorder: a critical review of current evidence. Bipolar disorders, 2004, Volume: 6, Issue:1 Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Dopamine Agonists; H	2004
Atypical antipsychotics in the treatment of children and adolescents: clinical applications. The Journal of clinical psychiatry, 2004, Volume: 65 Suppl 6 Topics: Adolescent; Age Factors; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders;	2004
Novel antipsychotics in bipolar and schizoaffective mania. Acta psychiatrica Scandinavica, 2004, Volume: 109, Issue:6 Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Olanzapine; Psychotic Disorders; Ri	2004
Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. The Journal of clinical psychiatry, 2004, Volume: 65, Issue:11 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorde	2004
[Therapeutic and pharmacological effects of second-generation antipsychotics on drug-resistant bipolar depression]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, 2004, Volume: 106, Issue:8 Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety; Benzodiazepines; Bip	2004
The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania. The Journal of clinical psychiatry, 2005, Volume: 66 Suppl 3 Topics: Acute Disease; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodia	2005
Women are not the same as men: specific clinical issues for female patients with bipolar disorder. Bipolar disorders, 2005, Volume: 7 Suppl 1 Topics: Anticonvulsants; Antidepressive Agents; Benzodiazepines; Bipolar Disorder; Counseling; Dibenzothiaze	2005
Risperidone for bipolar disorders. Expert review of neurotherapeutics, 2005, Volume: 5, Issue:2 Topics: Antipsychotic Agents; Bipolar Disorder; Blood Glucose; Body Weight; Clinical Trials as Topic; Drug E	2005
Risperidone: a review of its use in the treatment of bipolar mania. CNS drugs, 2005, Volume: 19, Issue:5 Topics: Animals; Antipsychotic Agents; Bipolar Disorder; Humans; Psychiatric Status Rating Scales; Risperido	2005
Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar disorders, 2005, Volume: 7 Suppl 4 Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Humans;	2005
A typical mood stabilizers: a "typical role for atypical antipsychotics. Acta psychiatrica Scandinavica. Supplementum, 2005, Issue:426 Topics: Affect; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Clozapin	2005
Management options for bipolar disorder in children and adolescents. Paediatric drugs, 2005, Volume: 7, Issue:5 Topics: Adolescent; Benzodiazepines; Bipolar Disorder; Carbamazepine; Child; Clozapine; Dibenzothiazepines;	2005
Typical and atypical antipsychotics in bipolar depression. The Journal of clinical psychiatry, 2005, Volume: 66, Issue:11 Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Dopamine D2 Receptor An	2005
Risperidone alone or in combination for acute mania. The Cochrane database of systematic reviews, 2006, Jan-25, Issue:1 Topics: Antipsychotic Agents; Bipolar Disorder; Chemotherapy, Adjuvant; Haloperidol; Humans; Lithium; Random	2006
A systematic review of the efficacy and safety of second generation antipsychotics in the treatment of mania. European psychiatry : the journal of the Association of European Psychiatrists, 2006, Volume: 21, Issue:1 Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Dibenzothiazepines; Humans; Olan	2006
[Treatment of bipolar mania with risperidone]. Psychiatrische Praxis, 2006, Volume: 33 Suppl 1 Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Clinical Trials as Topic; Drug Therapy, Combina	2006
Risperidone treatment of bipolar mania. The Annals of pharmacotherapy, 2006, Volume: 40, Issue:4 Topics: Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; Databases, Factual; Drug Therapy,	2006
Haloperidol alone or in combination for acute mania. The Cochrane database of systematic reviews, 2006, Jul-19, Issue:3 Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Carbamazepine; D	2006
Long-term use of atypical antipsychotics in bipolar disorder. Pharmacotherapy, 2006, Volume: 26, Issue:8 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Drug Admi	2006
Risperidone in long-term treatment for bipolar disorder. The Cochrane database of systematic reviews, 2006, Oct-18, Issue:4 Topics: Antipsychotic Agents; Bipolar Disorder; Humans; Long-Term Care; Risperidone	2006
Long-term pharmacological treatment of bipolar disorders. Neuro endocrinology letters, 2007, Volume: 28 Suppl 1 Topics: Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cl	2007
Treatment of bipolar disorder: the evolving role of atypical antipsychotics. The American journal of managed care, 2007, Volume: 13, Issue:7 Suppl Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Bipolar Disorder; Diabete	2007
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. The Journal of clinical psychiatry, 2008, Volume: 69, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Double-Bl	2008
Mania, psychosis, and antipsychotics. The Journal of clinical psychiatry, 1996, Volume: 57 Suppl 3 Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Bipolar Disorder; Clozapine; Humans; Prognosi	1996
Antipsychotics in bipolar disorder. The Journal of clinical psychiatry, 1996, Volume: 57 Suppl 9 Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; D	1996
Mood stabilizer combinations: a review of safety and efficacy. The American journal of psychiatry, 1998, Volume: 155, Issue:1 Topics: Acetates; Amines; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Calcium Channel Blockers;	1998
Antipsychotic agents and bipolar disorder. The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 1 Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Cl	1998
Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. Journal of affective disorders, 1998, Volume: 48, Issue:2-3 Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cl	1998
Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. The American journal of psychiatry, 1998, Volume: 155, Issue:8 Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Clozapine; Confidence Intervals; Female;	1998
Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations. The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 12 Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Clozapine; Comorb	1998
Treatment of special populations with the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 12 Topics: Adult; Age Factors; Aged; Algorithms; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clini	1998
Tardive dyskinesia in affective disorders. The Journal of clinical psychiatry, 1999, Volume: 60 Suppl 5 Topics: Adult; Affective Disorders, Psychotic; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipol	1999
Antipsychotic drug side effect issues in bipolar manic patients. The Journal of clinical psychiatry, 2000, Volume: 61 Suppl 8 Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Clozapine; Dibenz	2000
Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases. The Journal of clinical psychiatry, 2000, Volume: 61, Issue:9 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dose-Response Relationship, Drug; Fe	2000
An ever-increasing pharmacopoeia for the management of patients with bipolar disorder. The Journal of clinical psychiatry, 2000, Volume: 61 Supp 13 Topics: Acetates; Amines; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Carbamaz	2000
New treatments for bipolar disorder: the role of atypical neuroleptic agents. The Journal of clinical psychiatry, 2000, Volume: 61 Suppl 14 Topics: Acute Disease; Algorithms; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazep	2000
Does risperidone have a place in the treatment of nonschizophrenic patients? International clinical psychopharmacology, 2001, Volume: 16, Issue:1 Topics: Bipolar Disorder; Clinical Trials as Topic; Dementia; Humans; Mental Disorders; Obsessive-Compulsive	2001
Optimal dosing with risperidone: updated recommendations. The Journal of clinical psychiatry, 2001, Volume: 62, Issue:4 Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Top	2001
Use of atypical antipsychotics in mood disorders. Current opinion in investigational drugs (London, England : 2000), 2001, Volume: 2, Issue:7 Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Clozapine; Depres	2001
The role of novel antipsychotics in bipolar disorders. The Journal of clinical psychiatry, 2002, Volume: 63 Suppl 3 Topics: Acute Disease; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Haloperidol; Humans; Lithium; Ol	2002

Article	Year
Efficacy and safety of palmitoylethanolamide as an adjunctive treatment for acute mania: A randomized, double-blind, placebo-controlled trial. Psychiatry and clinical neurosciences, 2022, Volume: 76, Issue:10 Topics: Amides; Antimanic Agents; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Double-Bli	2022
Efficacy of melatonin as an adjunct in the treatment of acute mania: a double-blind and placebo-controlled trial. International clinical psychopharmacology, 2020, Volume: 35, Issue:2 Topics: Adolescent; Adult; Aged; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Female; H	2020
A Randomized, Double-Blind Placebo-Controlled Trial on Effectiveness and Safety of Celecoxib Adjunctive Therapy in Adolescents with Acute Bipolar Mania. Journal of child and adolescent psychopharmacology, 2017, Volume: 27, Issue:6 Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Celecoxib; Child; Double-Blind Method; Drug Therapy,	2017
A randomized, double-blind, placebo- and risperidone-controlled study on valnoctamide for acute mania. Bipolar disorders, 2017, Volume: 19, Issue:4 Topics: Adult; Amides; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dose-Response Relationship,	2017
Effectiveness, Adverse Effects and Drug Compliance of Long-Acting Injectable Risperidone in Children and Adolescents. Clinical drug investigation, 2017, Volume: 37, Issue:10 Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Child; Conduct Disorder; Delayed-Action Preparat	2017
GERI-BD: A Randomized Double-Blind Controlled Trial of Lithium and Divalproex in the Treatment of Mania in Older Patients With Bipolar Disorder. The American journal of psychiatry, 2017, 11-01, Volume: 174, Issue:11 Topics: Aged; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Drug Therapy, C	2017
Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA. Journal of comparative effectiveness research, 2018, Volume: 7, Issue:7 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cost-Benefit Analysis; Dela	2018
A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone. Schizophrenia research, 2019, Volume: 204 Topics: Adolescent; Adult; Antipsychotic Agents; Anxiety; Bipolar Disorder; Brief Psychiatric Rating Scale;	2019
Risperidone adjunctive therapy duration in the maintenance treatment of bipolar I disorder: A post hoc analysis. Journal of affective disorders, 2019, 03-01, Volume: 246 Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Double-Blind	2019
Risperidone versus risperidone plus sodium valproate for treatment of bipolar disorders: a randomized, double-blind clinical-trial. Global journal of health science, 2014, Jul-29, Volume: 6, Issue:6 Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Femal	2014
The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia. Bipolar disorders, 2015, Volume: 17, Issue:5 Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Body Mass In	2015
Placebo-controlled trial of valproic Acid versus risperidone in children 3-7 years of age with bipolar I disorder. Journal of child and adolescent psychopharmacology, 2015, Volume: 25, Issue:4 Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Child; Child, Preschool; Double-Blind Meth	2015
Placebo-controlled trial of valproic Acid versus risperidone in children 3-7 years of age with bipolar I disorder. Journal of child and adolescent psychopharmacology, 2015, Volume: 25, Issue:4 Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Child; Child, Preschool; Double-Blind Meth	2015
Placebo-controlled trial of valproic Acid versus risperidone in children 3-7 years of age with bipolar I disorder. Journal of child and adolescent psychopharmacology, 2015, Volume: 25, Issue:4 Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Child; Child, Preschool; Double-Blind Meth	2015
Placebo-controlled trial of valproic Acid versus risperidone in children 3-7 years of age with bipolar I disorder. Journal of child and adolescent psychopharmacology, 2015, Volume: 25, Issue:4 Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Child; Child, Preschool; Double-Blind Meth	2015
Efficacy and Safety of Risperidone and Quetiapine in Adolescents With Bipolar II Disorder Comorbid With Conduct Disorder. Journal of clinical psychopharmacology, 2015, Volume: 35, Issue:5 Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Body Mass Index; Conduct Disorder; Female; Human	2015
Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial. Molecular psychiatry, 2016, Volume: 21, Issue:8 Topics: Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Combined Modality	2016
Depression and Suicidality Outcomes in the Treatment of Early Age Mania Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, Volume: 54, Issue:12 Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Child; Depression; Female; Hum	2015
Treatment of Early-Age Mania: Outcomes for Partial and Nonresponders to Initial Treatment. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, Volume: 54, Issue:12 Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Child; Drug Therapy, Combination; Female; Humans; Li	2015
Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial. The Journal of clinical psychiatry, 2008, Volume: 69, Issue:8 Topics: Adult; Amphetamine-Related Disorders; Antipsychotic Agents; Bipolar Disorder; Cocaine-Related Disord	2008
Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. Journal of affective disorders, 2009, Volume: 115, Issue:3 Topics: Adolescent; Adult; Aged; Analysis of Variance; Anxiety; Anxiety Disorders; Bipolar Disorder; Comorbi	2009
Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis. Archives of general psychiatry, 2009, Volume: 66, Issue:4 Topics: Adolescent; Adult; Antipsychotic Agents; Atrophy; Bipolar Disorder; Cognitive Behavioral Therapy; Co	2009
Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar disorders, 2009, Volume: 11, Issue:7 Topics: Adolescent; Age Factors; Antipsychotic Agents; Bipolar Disorder; Body Mass Index; Child; Diagnostic	2009
Risperidone in the treatment of mixed state bipolar patients: results from a 24-week, multicenter, open-label study in Korea. Psychiatry and clinical neurosciences, 2010, Volume: 64, Issue:1 Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Combination; Female;	2010
A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar disorders, 2009, Volume: 11, Issue:8 Topics: Adolescent; Adult; Aged; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Double-Blind Meth	2009
Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biological psychiatry, 2010, Jul-15, Volume: 68, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Double-Blind	2010
Comparison of olanzapine and risperidone in the EMBLEM Study: translation of randomized controlled trial findings into clinical practice. International clinical psychopharmacology, 2010, Volume: 25, Issue:5 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Therapy, Combination; Female; H	2010
Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial. Bipolar disorders, 2010, Volume: 12, Issue:4 Topics: Adult; Amides; Animals; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method	2010
Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder. Bipolar disorders, 2010, Volume: 12, Issue:6 Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Child; Double-Blind Method; Fe	2010
Long-term efficacy of risperidone long-acting injectable in bipolar disorder with psychotic features: a prospective study of 3-year outcomes. International clinical psychopharmacology, 2011, Volume: 26, Issue:3 Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Drug Administration Schedule; Female; Humans; Injecti	2011
Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone. The Journal of clinical psychiatry, 2011, Volume: 72, Issue:9 Topics: Adolescent; Adult; Aged; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; F	2011
Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder: fMRI outcomes. Psychiatry research, 2011, Jul-30, Volume: 193, Issue:1 Topics: Adolescent; Analysis of Variance; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Brain; C	2011
A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. The Journal of clinical psychiatry, 2011, Volume: 72, Issue:12 Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; GABA Agents; Hum	2011
Pharmacotherapy impacts functional connectivity among affective circuits during response inhibition in pediatric mania. Behavioural brain research, 2012, Jan-15, Volume: 226, Issue:2 Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Brain; Brain Mapping; Child; Female; Humans; Inhibit	2012
Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms. BMC psychiatry, 2011, Oct-28, Volume: 11 Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Bipolar D	2011
Characteristics of responders and non-responders to risperidone monotherapy or placebo in co-occurring bipolar disorder and anxiety disorder. European psychiatry : the journal of the Association of European Psychiatrists, 2013, Volume: 28, Issue:3 Topics: Adult; Antipsychotic Agents; Anxiety Disorders; Bipolar Disorder; Double-Blind Method; Female; Human	2013
Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder. Journal of child and adolescent psychopharmacology, 2011, Volume: 21, Issue:6 Topics: Adolescent; Aggression; Antimanic Agents; Antipsychotic Agents; Attention Deficit and Disruptive Beh	2011
A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Archives of general psychiatry, 2012, Volume: 69, Issue:5 Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Child; Female; Humans; Lithium Carbonate; Male; Psyc	2012
Risperidone and divalproex differentially engage the fronto-striato-temporal circuitry in pediatric mania: a pharmacological functional magnetic resonance imaging study. Journal of the American Academy of Child and Adolescent Psychiatry, 2012, Volume: 51, Issue:2 Topics: Adolescent; Affect; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Brain Mapping; Child; C	2012
Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania. International journal of psychiatry in clinical practice, 2012, Volume: 16, Issue:3 Topics: Acute Disease; Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Body Wei	2012
A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2012, Volume: 22, Issue:11 Topics: Adolescent; Adult; Affective Symptoms; Aged; Antipsychotic Agents; Bipolar Disorder; Delayed-Action	2012
Treatment moderators and predictors of outcome in the Treatment of Early Age Mania (TEAM) study. Journal of the American Academy of Child and Adolescent Psychiatry, 2012, Volume: 51, Issue:9 Topics: Adolescent; Age Factors; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Attention Deficit	2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:8 Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso	2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:8 Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso	2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:8 Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso	2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:8 Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso	2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:8 Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso	2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:8 Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso	2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:8 Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso	2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:8 Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso	2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:8 Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso	2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:8 Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso	2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:8 Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso	2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:8 Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso	2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:8 Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso	2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:8 Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso	2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:8 Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso	2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:8 Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso	2012
Relative effectiveness of adjunctive risperidone on manic and depressive symptoms in mixed mania. International clinical psychopharmacology, 2013, Volume: 28, Issue:2 Topics: Adult; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Diagnostic an	2013
Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain. Journal of affective disorders, 2002, Volume: 72, Issue:1 Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Drug Tolerance; Female; Humans;	2002
Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. The British journal of psychiatry : the journal of mental science, 2003, Volume: 182 Topics: Adult; Aged; Antimanic Agents; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Brief	2003
Combination pharmacotherapy in children and adolescents with bipolar disorder. Biological psychiatry, 2003, Jun-01, Volume: 53, Issue:11 Topics: Adolescent; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Attention Deficit Disorde	2003
Risperidone in acute and continuation treatment of mania. International clinical psychopharmacology, 2003, Volume: 18, Issue:4 Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Drug Administration	2003
Rate-decreasing effects of the atypical neuroleptic risperidone attenuated by conditions of reinforcement in a woman with mental retardation. Journal of applied behavior analysis, 2003,Summer, Volume: 36, Issue:2 Topics: Adult; Antipsychotic Agents; Attention; Autistic Disorder; Behavior Therapy; Bipolar Disorder; Discr	2003
Antipsychotic-induced weight gain: bipolar disorder and leptin. Journal of clinical psychopharmacology, 2003, Volume: 23, Issue:4 Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body M	2003
1-year follow-up of patients treated with risperidone and topiramate for a manic episode. The Journal of clinical psychiatry, 2003, Volume: 64, Issue:7 Topics: Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Dis	2003
Acute and continuation risperidone monotherapy in mania. Human psychopharmacology, 2004, Volume: 19, Issue:1 Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Drug Administration Schedule; Fe	2004
Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. The American journal of psychiatry, 2004, Volume: 161, Issue:6 Topics: Acute Disease; Adult; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Female; Humans; M	2004
Lithium treatment of acute mania in adolescents: a placebo-controlled discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry, 2004, Volume: 43, Issue:8 Topics: Acute Disease; Adolescent; Aggression; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Bri	2004
Risperidone in combination with mood stabilizers for acute mania: a multicentre, open study. International clinical psychopharmacology, 2004, Volume: 19, Issue:5 Topics: Acute Disease; Adult; Antipsychotic Agents; Asia; Basal Ganglia Diseases; Bipolar Disorder; Drug The	2004
Risperidone does not affect steady-state pharmacokinetics of divalproex sodium in patients with bipolar disorder. Clinical pharmacokinetics, 2004, Volume: 43, Issue:11 Topics: Adolescent; Adult; Aged; Antimanic Agents; Antipsychotic Agents; Area Under Curve; Bipolar Disorder;	2004
A prospective 4-5 year follow-up of juvenile onset bipolar disorder. Bipolar disorders, 2004, Volume: 6, Issue:5 Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Carbamazep	2004
The antidepressant effects of risperidone and olanzapine in bipolar disorder. The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 2004,Fall, Volume: 11, Issue:2 Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body W	2004
Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. Journal of affective disorders, 2004, Volume: 82 Suppl 1 Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Child; Child, Preschool; Drug Therapy, Combinati	2004
Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2005, Volume: 15, Issue:1 Topics: Adolescent; Adult; Aged; Analysis of Variance; Bipolar Disorder; Dopamine Antagonists; Double-Blind	2005
Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study. Progress in neuro-psychopharmacology & biological psychiatry, 2005, Volume: 29, Issue:1 Topics: Acute Disease; Adolescent; Adult; Aged; Antimanic Agents; Antipsychotic Agents; Basal Ganglia Diseas	2005
Risperidone and paroxetine given singly and in combination for bipolar depression. The Journal of clinical psychiatry, 2004, Volume: 65, Issue:12 Topics: Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Drug Administra	2004
An open-label trial of risperidone in children and adolescents with bipolar disorder. Journal of child and adolescent psychopharmacology, 2005, Volume: 15, Issue:2 Topics: Adolescent; Bipolar Disorder; Child; Female; Humans; Male; Prospective Studies; Regression Analysis;	2005
Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. The Journal of clinical psychiatry, 2005, Volume: 66, Issue:8 Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Female; Humans; Logistic Models;	2005
Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. The British journal of psychiatry : the journal of mental science, 2005, Volume: 187 Topics: Acute Disease; Adult; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Female; Humans; M	2005
Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biological psychiatry, 2005, Oct-01, Volume: 58, Issue:7 Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Child; Child, Preschool; Female; Humans; Ma	2005
An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder. International clinical psychopharmacology, 2006, Volume: 21, Issue:1 Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Female; Humans; Male; Middle Age	2006
Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. The American journal of psychiatry, 2006, Volume: 163, Issue:2 Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Depressive Di	2006
Adjunctive risperidone, olanzapine and quetiapine for the treatment of hospitalized patients with bipolar I disorder: a retrospective study. Progress in neuro-psychopharmacology & biological psychiatry, 2006, Sep-30, Volume: 30, Issue:7 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines	2006
A one-year open-label trial of risperidone augmentation in lithium nonresponder youth with preschool-onset bipolar disorder. Journal of child and adolescent psychopharmacology, 2006, Volume: 16, Issue:3 Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Child; Child, Preschool; Drug Therapy, Combinati	2006
Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders. Human psychopharmacology, 2006, Volume: 21, Issue:7 Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Catecholamines; Ch	2006
Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. Therapeutic drug monitoring, 2006, Volume: 28, Issue:5 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Drug Interactions; Female	2006
Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder. Journal of pharmacokinetics and pharmacodynamics, 2007, Volume: 34, Issue:2 Topics: Acute Disease; Administration, Oral; Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Computer S	2007
Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. The Journal of clinical psychiatry, 2006, Volume: 67, Issue:11 Topics: Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Appetite; Benzodiazepines; Bipolar Disor	2006
Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder. Progress in neuro-psychopharmacology & biological psychiatry, 2007, Aug-15, Volume: 31, Issue:6 Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Drug Delivery Systems; Female; Humans; Male; Middle A	2007
Facial emotion processing in acutely ill and euthymic patients with pediatric bipolar disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2007, Volume: 46, Issue:8 Topics: Acute Disease; Adolescent; Antipsychotic Agents; Bipolar Disorder; Child; Drug Therapy, Combination;	2007
A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder. Acta psychiatrica Scandinavica. Supplementum, 2007, Issue:434 Topics: Administration, Oral; Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Benzodiazepine	2007
Risperidone monotherapy in manic inpatients: an open label, multicentre trial. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2007, Volume: 8, Issue:4 Topics: Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Female; Human	2007
Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study. The Journal of clinical psychiatry, 2007, Volume: 68, Issue:8 Topics: Adult; Antipsychotic Agents; Attention; Bipolar Disorder; Cognition; Cognition Disorders; Dibenzothi	2007
Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients. International clinical psychopharmacology, 2008, Volume: 23, Issue:2 Topics: Adult; Aged; Ambulatory Care; Antipsychotic Agents; Bipolar Disorder; Delayed-Action Preparations; F	2008
Psychotic symptoms in patients with bipolar mania. Journal of affective disorders, 2008, Volume: 111, Issue:2-3 Topics: Adolescent; Adult; Age of Onset; Bipolar Disorder; Comorbidity; Diagnostic and Statistical Manual of	2008
Risperidone in the treatment of affective illness and obsessive-compulsive disorder. The Journal of clinical psychiatry, 1995, Volume: 56, Issue:9 Topics: Adult; Ambulatory Care; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Drug Administra	1995
Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. The Journal of clinical psychiatry, 1995, Volume: 56, Issue:11 Topics: Aged; Bipolar Disorder; Chronic Disease; Comorbidity; Dementia; Female; Hospitalization; Humans; Hyp	1995
Risperidone in the treatment of mania. The Journal of clinical psychiatry, 1996, Volume: 57, Issue:6 Topics: Acute Disease; Adult; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Confidence Intervals; D	1996
Long-term risperidone treatment in bipolar disorder: 6-month follow up. International clinical psychopharmacology, 1997, Volume: 12, Issue:6 Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Combination; Female;	1997
Treatment of refractory rapid cycling bipolar disorder with risperidone. Journal of clinical psychopharmacology, 1998, Volume: 18, Issue:2 Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Male; Middle Aged; Pilot Projects; Ps	1998
Tiagabine appears not to be efficacious in the treatment of acute mania. The Journal of clinical psychiatry, 1999, Volume: 60, Issue:11 Topics: Acute Disease; Adult; Anticonvulsants; Bipolar Disorder; Drug Therapy, Combination; Female; GABA Ant	1999
Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. International clinical psychopharmacology, 2000, Volume: 15, Issue:5 Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Drug Therapy, Combination; Female; Human	2000
A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. The Journal of clinical psychiatry, 2000, Volume: 61, Issue:9 Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Bipolar Disorder; Body Weight;	2000
Fixed-dosed risperidone in mania: an open experimental trial. International clinical psychopharmacology, 2001, Volume: 16, Issue:2 Topics: Administration, Oral; Adult; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Male; Middle Ag	2001
A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder. Journal of clinical psychopharmacology, 2001, Volume: 21, Issue:4 Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Female; Hal	2001
Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD). The Journal of clinical psychiatry, 2001, Volume: 62, Issue:8 Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar	2001
Role of risperidone in bipolar II: an open 6-month study. Journal of affective disorders, 2001, Volume: 67, Issue:1-3 Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Drug Administration Schedule; Female; Humans; Male; M	2001
The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:2 Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Dose-Response Relatio	2002
Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. The American journal of psychiatry, 2002, Volume: 159, Issue:7 Topics: Acute Disease; Adolescent; Adult; Aged; Antimanic Agents; Antiparkinson Agents; Antipsychotic Agents	2002

risperidone and Affective Psychosis, Bipolar